Anti-CD47 monoclonal antibodies and uses thereof

Abstract

Anti-CD47 monoclonal antibodies secreted by a hybridoma cell line having the deposit number CCTCC NO: C2018135, and their use in combination with monoclonal antibodies, specific antibodies and / or tumor therapeutic agents.

Description

[Technical field]

[0001] The present invention relates to the fields of autoimmune disease treatment and molecular immunology. It relates to anti-CD47 antibodies, pharmaceutical compositions containing same and uses thereof. In particular, the present invention relates to anti-CD47 monoclonal antibodies. [Background technology]

[0002] CD47 is also called integrin associated protein (IAP). CD47 is a five-transmembrane protein with a molecular weight of approximately 50 kDa, belonging to the immunoglobulin superfamily. Its extracellular N-terminus is an IgV domain that connects to αvβ3 (CD51 / CD61) and αIIbβ3 (CD41 / CD61) integrins. CD47 is involved in various physiological functions, including cell migration, activation of T cells and dendritic cells (DCs), and axon development.

[0003] CD47 is expressed in all types of cells, including erythrocytes, and is highly expressed in tumor cells. CD47 has two ligands, Signal Regulatory Protein α (SIRPα) and Thrombospondin-1 (TSP1). SIRPα is a series of receptor-type transmembrane glycoproteins containing immunoglobulin domains, belonging to the SIRP family, and is mainly expressed in macrophages and neuronal cells. In the CD47-SIRPα pathway, CD47 protein binds to SIRPα and phosphorylates its immunoreceptor tyrosine-based inhibitory motif ITIM, then recruits SHP-1 protein in cells, resulting in a series of cascade reactions that inhibit the phagocytosis of macrophages (Matozaki T, Murata Y, Okazawa H, et al. Functions and molecular mechanisms of the CD47-SIRPα signalling pathway. Trends in cell biology, 2009, 19(2): 72-80). However, normal red blood cells are not phagocytosed because CD47 on the cell membrane binds to SIPRα on macrophages and generates an inhibitory signal. (Oldenborg PA, Zheleznyak A, Fang YF, et al. Role of CD47 as a marker of self on red blood cells. Science, 2000, 288(5473): 2051-2054.) TSP1, a homotrimer composed of three peptide chains, is involved in processes such as cell proliferation, apoptosis, adhesion, migration, and angiogenesis by interacting with other cell surface receptors, matrix components, and growth factors (Jiang P, Lagenaur CF, Narayanan V. Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule. Journal of Biological Chemistry 1999. 274: 559-62).

[0004] Macrophages are derived from monocytes, which in turn originate from precursor cells in the bone marrow. Their main function is to phagocytose cellular debris and pathogens in the form of fixed or free cells and to activate lymphocytes or other immune cells to respond to pathogens. Previous studies have suggested that tumor cells have a mechanism to avoid phagocytosis by macrophages. During the process of tumor cell proliferation, they form specific proteins on their surface that reveal their tumor identity, such as calreticulin, which attracts and phagocytose macrophages. On the other hand, the CD47-SIRPα pathway activates an inhibitor of macrophage phagocytosis, so that macrophages with SIRPα mistake tumor cells that highly express CD47 for normal cells, and the tumor cells escape phagocytosis by macrophages (CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Jaiswal S, Jamieson CHM, Pang WW, et al. Cell, 2009, 138(3) 271-285).

[0005] Previous studies have shown that anti-CD47 antibodies mainly kill tumor cells through the following two mechanisms: 1. Anti-CD47 antibodies bind to CD47 and block the CD47-SIRPα pathway, causing macrophages to phagocytose. 2. Anti-CD47 antibodies exert their tumor-killing effect through DC cells and CD8+T cells. DC cells phagocytose tumor cells through the synergistic effect of anti-CD47 antibodies and phagocytosis-promoting molecules such as calreticulin, and present tumor-associated antigens to CD8+T cells, further enabling CD8+T cells to exert a specific killing effect against tumors (CD47 blockade as another immune checkpoint therapy for cancer. Vonderheide R H. Nature Medicine, 2015, 21(10): 1122). These two mechanisms suggest that anti-CD47 antibodies are highly likely to have the ability to simultaneously activate nonspecific and specific immunity.

[0006] At present, anti-CD47 monoclonal antibody drugs have a wide range of application prospects and good tumor treatment effects, so they can be used to treat various tumors. Anti-CD47 monoclonal antibody drug Hu5F9-G4 can effectively inhibit the growth and metastasis of malignant blood diseases and solid tumors in preclinical trials (Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies[J] Chao MP, McKenna KM, Cha A, et al., 2016). Among them, the amino acid sequence of the heavy chain is as shown in SEQ ID NO: 85, and the amino acid sequence of the light chain is as shown in SEQ ID NO: 86.

[0007] Therefore, it is of great significance to develop an antibody drug for tumor therapy that has high affinity for CD47, thereby improving the therapeutic effect and reducing toxicity and side effects. Summary of the Invention

[0008] The present inventors expressed recombinant human CD47 using a mammalian cell expression system, immunized mice with this as an antigen, and obtained hybridoma cells by fusing mouse spleen cells with myeloma cells. By screening a large number of samples, the following hybridoma cell lines were obtained.

[0009] The inventors have discovered the following:

[0010] The hybridoma cell line LT012 can secrete a monoclonal antibody (named 6F7) that specifically binds to CD47, and the monoclonal antibody can compete with the receptor SIRPα ECD-hFc-Biotin to bind to CD47, effectively blocking the binding of SIRPα to CD47, and promoting the phagocytosis of tumor cells by macrophages.

[0011] Furthermore, the present inventors have obtained humanized antibodies of monoclonal antibody 6F7 (designated 6F7H1L1, 6F7H2L2 and 6F7H3L3).

[0012] Accordingly, the present invention provides the following inventions.

[0013] By technical means well known to those skilled in the art, for example, the amino acid sequence of the CDR region of the antibody sequence in the VBASE2 database was analyzed, and the results were: the antibodies 6F7, 6F7H1L1, 6F7H2L2 and 6F7H3L3 of the present invention have the same HCDR1-3 and LCDR1-3, The amino acid sequences of the three CDR regions of the heavy chain variable region are as follows: HCDR1: GYTFTSYW (SEQ ID NO: 5), HCDR2: IDPSDSET (SEQ ID NO: 6), HCDR3: ARLYRWYFDV (SEQ ID NO: 7); The amino acid sequences of the three CDR regions of the light chain variable region are as follows: LCDR1: EIVGTY (SEQ ID NO: 8), LCDR2:GAS (SEQ ID NO: 9), LCDR3: GQSYNFPYT (sequence number 10). In some embodiments, the antibody of the invention is selected from the group consisting of: Amino acid sequence of the heavy chain of 6F7H1L1(G1M) (SEQ ID NO:59) Amino acid sequence of the light chain of 6F7H1L1(G1M) (SEQ ID NO:60) Amino acid sequence of the heavy chain of 6F7H2L2(G1M) (SEQ ID NO:61) Amino acid sequence of the light chain of 6F7H2L2 (G1M) (SEQ ID NO: 62) Amino acid sequence of the heavy chain of 6F7H3L3 (G1M) (SEQ ID NO: 63) Amino acid sequence of the light chain of 6F7H3L3 (G1M) (SEQ ID NO: 64) Amino acid sequence of the heavy chain of 6F7H1L1 (hG4) (SEQ ID NO:65) Amino acid sequence of the light chain of 6F7H1L1 (hG4) (SEQ ID NO:66) Amino acid sequence of the heavy chain of 6F7H2L2 (hG4) (SEQ ID NO:67) Amino acid sequence of the light chain of 6F7H2L2 (hG4) (SEQ ID NO:68) Amino acid sequence of the heavy chain of 6F7H3L3 (hG4) (SEQ ID NO:69) Amino acid sequence of the light chain of 6F7H3L3 (hG4) (SEQ ID NO: 70)

[0014] In one aspect of the invention, the invention relates to an isolated polypeptide comprising a sequence as set forth in SEQ ID NO:5, 6 or 7, said polypeptide specifically binding to human CD47 as part of an anti-human CD47 antibody, said antibody further comprising a sequence as set forth in SEQ ID NO:8, 9 or 10.

[0015] In one aspect of the invention, the invention relates to an isolated polypeptide comprising a sequence as set forth in SEQ ID NO:8, 9 or 10, said polypeptide specifically binding to human CD47 as part of an anti-human CD47 antibody, said antibody further comprising a sequence as set forth in SEQ ID NO:5, 6 or 7.

[0016] In one aspect of the invention, the invention relates to an isolated polypeptide comprising a sequence as set forth in SEQ ID NO: 2, 12, 16 or 20 or a variant thereof, said polypeptide specifically binding to human CD47 as part of an anti-human CD47 antibody, said antibody further correspondingly comprising a sequence as set forth in SEQ ID NO: 4, 14, 18 or 22, respectively, or a variant thereof, said variant having a sequence identity of at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% relative to the corresponding sequence. , 95%, 96%, 97%, 98% or 99% or more sequence identity, or have one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence, or

[0017] One aspect of the invention relates to an isolated polypeptide comprising a sequence as set forth in SEQ ID NO: 4, 14, 18 or 22 or a variant thereof, said polypeptide specifically binding to human CD47 as part of an anti-human CD47 antibody, said monoclonal antibody correspondingly further comprising a sequence as set forth in SEQ ID NO: 2, 12, 16 or 20 or a variant thereof, said variant correspondingly being at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 1 %, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity, or have one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence.

[0018] In an embodiment of the invention, the antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, Fab / c, a complementarity determining region (CDR) fragment, a single chain antibody (e.g., scFv), a bivalent antibody, or a domain antibody.

[0019] In an embodiment of the invention, the antibody that specifically binds to CD47 is a humanized antibody, a chimeric antibody, a multispecific antibody (eg, a bispecific antibody).

[0020] In an embodiment of the present invention, the antibody that specifically binds to CD47 has a binding affinity of about 10 -5 Less than m, e.g., about 10 -6 Less than M, about 10 -7 Less than M, about 10 -8 Less than M, about 10 -9 Less than M or about 10 -10 K less than M or less D Preferably, the above K D is measured by the Fortebio molecular interaction instrument.

[0021] In an embodiment of the invention, the antibody that specifically binds to CD47 binds to human CD47 protein with an EC50 of less than about 100 nM, for example, less than about 10 nM, less than about 1 nM, less than about 0.9 nM, less than about 0.8 nM, less than about 0.7 nM, less than about 0.6 nM, less than about 0.5 nM, less than about 0.4 nM, less than about 0.3 nM, less than about 0.2 nM, less than about 0.1 nM or less. Specifically, the EC50 is measured by indirect ELISA.

[0022] In an embodiment of the invention, the antibody that specifically binds to CD47 comprises a constant region and the constant region is derived from a non-murine species, e.g., from a human antibody, preferably from human IgG, more preferably from IgG1 or IgG4.

[0023] In an embodiment of the present invention, the constant region of the antibody that specifically binds to CD47 is derived from a human. For example, the heavy chain constant region employs an Ig gamma-1 chain C region, preferably the Ig gamma-1 chain C region (sequence number 58) having GenBank accession number ACCESSION:P01857, or an Ig gamma-4 chain C region, preferably the Ig gamma-4 chain C region (sequence number 56) having GenBank accession number ACCESSION:P01861.1, and the light chain constant region employs an Ig kappa chain C region, preferably the Ig kappa chain C region (sequence number 57) having GenBank accession number ACCESSION:P01834. The antibody of the present invention employs the following constant region in addition to the variable regions of 6F7H1L1, 6F7H2L2, and 6F7H3L3: the heavy chain constant region is an Ig gamma-1 chain C region, ACCESSION: P01857 (SEQ ID NO: 58), or the heavy chain constant region is an Ig gamma-4 chain C region, ACCESSION: P01861.1 (SEQ ID NO: 56), and further includes an S228P mutation for improving stability, and the light chain constant region is an Ig kappa chain C region, ACCESSION: P01834 (SEQ ID NO: 57). Another aspect of the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NO: 5, 6, or 7, which specifically binds to human CD47 as a part of an anti-human CD47 antibody, and which further comprises the sequence shown in SEQ ID NO: 8, 9, or 10.

[0024] In one aspect of the invention, the invention relates to an isolated polynucleotide encoding a polypeptide comprising a sequence as set forth in SEQ ID NO:8, 9 or 10, said polypeptide specifically binds to human CD47 as part of an anti-human CD47 antibody, said antibody further comprising a sequence as set forth in SEQ ID NO:5, 6 or 7.

[0025] In one aspect of the invention, there is provided an isolated polynucleotide encoding a polypeptide comprising a sequence as set forth in SEQ ID NO: 2, 12, 16 or 20 or a variant thereof, said polypeptide specifically binds to human CD47 as part of an anti-human CD47 antibody, said antibody further comprising a sequence selected from the sequence as set forth in SEQ ID NO: 4, 14, 18 or 22 or a variant thereof, respectively; The variant sequence has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to the corresponding sequence or has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence;

[0026] In one aspect of the invention, there is provided an isolated polynucleotide encoding a polypeptide comprising a sequence as set forth in SEQ ID NO: 4, 14, 18 or 22 or a variant thereof, said polypeptide specifically binds to human CD47 as part of an anti-human CD47 antibody, said antibody further comprising a sequence selected from the sequence as set forth in SEQ ID NO: 2, 12, 16 or 20, respectively, or a variant thereof; The variant has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to the corresponding sequence or has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence, Specifically, the polynucleotide molecule comprises or consists of the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:11, SEQ ID NO:15 or SEQ ID NO:19, or a sequence having at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity thereto.

[0027] Specifically, the polynucleotide molecule comprises or consists of the nucleotide sequence set forth in SEQ ID NO:3, SEQ ID NO:13, SEQ ID NO:17 or SEQ ID NO:21, or a sequence having at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity thereto.

[0028] In one aspect of the present invention, there is further provided the hybridoma cell line LT012 having deposit number CCTCC NO:2018135 and the monoclonal antibodies produced thereby.

[0029] The present invention further relates to the following aspects.

[0030] 1. A pharmaceutical composition, preferably for use in the treatment of tumors, comprising component A and component B, wherein component A is an antibody or an antigen-binding fragment thereof that specifically binds to CD47; wherein component B is one or more selected from component B1, component B2, and component B3, wherein component B1 is a bispecific antibody or an antigen-binding fragment thereof, component B2 is a tumor chemotherapeutic drug, and component B3 is an anti-PD-1 monoclonal antibody or an antigen-binding fragment thereof; Preferably, the composition further comprises a component C, which is a tumor therapeutic agent, and which is different from component B; For example, according to the Kabat, IMGT, Chothia or AbM numbering systems: The antibody that specifically binds to CD47 comprises the following CDR sequences contained in the heavy chain variable region and the light chain variable region: (1) HCDR1, HCDR2, and HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 2; LCDR1, LCDR2, LCDR3 contained in the light chain variable region shown in SEQ ID NO: 4, or (2) HCDR1, HCDR2, and HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 12; LCDR1, LCDR2, LCDR3 contained in the light chain variable region shown in SEQ ID NO: 14, or (3) HCDR1, HCDR2, and HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 16; LCDR1, LCDR2, LCDR3 contained in the light chain variable region shown in SEQ ID NO: 18, or (4) HCDR1, HCDR2, and HCDR3 contained in the heavy chain variable region represented by SEQ ID NO: 20; LCDR1, LCDR2, and LCDR3 contained in the light chain variable region shown in SEQ ID NO: 22 (Preferably, according to the IMGT numbering system, the antibody is HCDR1 comprising or consisting of the sequence shown in SEQ ID NO:5 or a variant thereof, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO:6 or a variant thereof, and The antibody comprises an HCDR3 comprising or composed of the sequence shown in SEQ ID NO: 7 or a variant thereof, LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:8 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:9 or a variant thereof; and and further comprising an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 10 or a variant thereof; Wherein, the bispecific antibody is an anti-PD-1-anti-CTLA4 antibody or an anti-PD-1-anti-VEGFA antibody or a combination of both, the bispecific antibody comprises a first protein functional domain and a second protein functional domain, in which the first protein functional domain targets PD-1 and the second protein functional domain targets CTLA4 or VEGFA, in which the first protein functional domain is an immunoglobulin and the second protein functional domain is a single chain antibody, or the first protein functional domain is a single chain antibody and the second protein functional domain is an immunoglobulin; Preferably, two single chain antibody molecules are connected to one immunoglobulin molecule (preferably, the two single chain antibody molecules are the same), preferably, the immunoglobulin is an IgG1 isoform (preferably, human IgG1 isoform), preferably, the single chain antibody is connected to the N-terminus or C-terminus of the immunoglobulin heavy chain, wherein the first protein functional domain and the second protein functional domain are independently one, two or more than two, preferably, the first protein functional domain is directly connected to the second protein functional domain or connected via a first connecting fragment. and / or the heavy chain variable region of the single chain antibody is connected directly or via a second connecting fragment to the light chain variable region of the single chain antibody, the first connecting fragment and the second connecting fragment being homologous or different, preferably, the connecting fragment is (GGGGS)n, n being a positive integer, more preferably, n being 1, 2, 3, 4, 5 or 6, preferably, the amino acid sequences of the first connecting fragment and the second connecting fragment are independently selected from SEQ ID NO: 119 and SEQ ID NO: 120, more preferably, the first connecting fragment and the second connecting fragment both comprise the amino acid sequence shown in SEQ ID NO: 120, Among them, when the bispecific antibody is an anti-PD-1-anti-CTLA4 antibody, The first protein functional region comprises HCDR1 to HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 87 and LCDR1 to LCDR3 contained in the light chain variable region shown in SEQ ID NO: 88 (preferably, according to the IMGT numbering system, the first protein functional region comprises or is composed of HCDR1, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 90 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 91 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 92 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 93 or a variant thereof; and comprising an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 94 or a variant thereof, The second protein functional region comprises HCDR1 to HCDR3 in the heavy chain variable region shown in SEQ ID NO: 95 and LCDR1 to LCDR3 in the light chain variable region shown in SEQ ID NO: 96 (preferably, according to the IMGT numbering system, the second protein functional region comprises or is composed of HCDR1, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 98 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 99 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 100 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 101 or a variant thereof; and comprising an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 102 or a variant thereof; or Among these, when the bispecific antibody is an anti-PD-1-anti-VEGFA antibody, The first protein functional region comprises HCDR1 to HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 103 and LCDR1 to LCDR3 contained in the light chain variable region shown in SEQ ID NO: 104 (preferably, according to the IMGT numbering system, the first protein functional region comprises HCDR1, LCDR2, LCDR3, LCDR4, LCDR5, LCDR6, LCDR7, LCDR8, LCDR9, LCDR10, LCDR11, LCDR12, LCDR13, LCDR14, LCDR15, LCDR16, LCDR17, LCDR18, LCDR19, LCDR20, LCDR21, LCDR22, LCDR23, LCDR24, LCDR25, LCDR26, LCDR27, LCDR28, LCDR29, LCDR30, LCDR310, LCDR311, LCDR32, LCDR33, LCDR34, LCDR35, LCDR36, LCDR37, LCDR38, LCDR40, LCDR41, LCDR42, LCDR43, LCDR44, LCDR45, LCDR46, LCDR47, LCDR50, LCDR51, LCDR52, LCDR53, LCDR54, LCDR55, LCDR56, LCDR61, LCDR62, LCDR73, LCDR74, LCDR85, LCDR96, LCDR97, LCDR98, LCDR109, LCDR110, LCDR111, LCDR112, LCDR113, LCDR114, LCDR115, LCDR115, LCDR116, LCDR117, LCDR118, LCDR119, LCDR120, LCDR130, LCDR141, LCDR152, LCDR163, LCDR174, LCDR185, LCDR195, LCDR196, LCD HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 106 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 107 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 108 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 109 or a variant thereof; and comprising an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 110 or a variant thereof, The second protein functional region comprises HCDR1 to HCDR3 in the heavy chain variable region shown in SEQ ID NO: 111 and LCDR1 to LCDR3 in the light chain variable region shown in SEQ ID NO: 112 (preferably, according to the IMGT numbering system, the second protein functional region comprises or is composed of the sequence shown in SEQ ID NO: 113 or a variant thereof, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 114 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 115 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 116 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 117 or a variant thereof; and comprising an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 118 or a variant thereof; Among them, The anti-PD1 monoclonal antibody comprises HCDR1 to HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 121 and LCDR1 to LCDR3 contained in the light chain variable region shown in SEQ ID NO: 122 (preferably, according to the IMGT numbering system, the anti-PD1 monoclonal antibody comprises HCDR1, which comprises the sequence shown in SEQ ID NO: 123 or a mutant thereof, or which is constituted thereby, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 124 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 125 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 126 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 127 or a variant thereof; and comprising an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 128 or a variant thereof; Therein, the sequence of said variant has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology to the corresponding sequence, or the sequence of said variant has one or more (preferably one, two or three) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence.

[0031] 2. The pharmaceutical composition according to item 1, wherein the antibody that specifically binds to CD47 further comprises a framework region FR of a heavy chain variable region and a framework region FR of a light chain variable region selected from the group consisting of: (1) The framework region FR of the heavy chain variable region includes FR-H1, FR-H2, FR-H3, and FR-H4, among which FR-H1 includes or is composed of the amino acid sequence of SEQ ID NO: 23 or a variant thereof, FR-H2 includes or is composed of the amino acid sequence of SEQ ID NO: 24 or a variant thereof, FR-H3 includes or is composed of the amino acid sequence of SEQ ID NO: 25 or a variant thereof, and FR-H4 includes or is composed of the amino acid sequence of SEQ ID NO: 26 or a variant thereof; The framework region FR of the light chain variable region includes FR-L1, FR-L2, FR-L3, and FR-L4, among which FR-L1 includes or is composed of the amino acid sequence of SEQ ID NO: 27 or a variant thereof, FR-L2 includes or is composed of the amino acid sequence of SEQ ID NO: 28 or a variant thereof, FR-L3 includes or is composed of the amino acid sequence of SEQ ID NO: 29 or a variant thereof, and FR-L4 includes or is composed of the amino acid sequence of SEQ ID NO: 30 or a variant thereof; (2) The framework region FR of the heavy chain variable region includes FR-H1, FR-H2, FR-H3, and FR-H4, among which FR-H1 includes or is composed of the amino acid sequence of SEQ ID NO: 31 or a variant thereof, FR-H2 includes or is composed of the amino acid sequence of SEQ ID NO: 32 or a variant thereof, FR-H3 includes or is composed of the amino acid sequence of SEQ ID NO: 33 or a variant thereof, and FR-H4 includes or is composed of the amino acid sequence of SEQ ID NO: 34 or a variant thereof; The framework region FR of the light chain variable region includes FR-L1, FR-L2, FR-L3, and FR-L4, among which FR-L1 includes or is composed of the amino acid sequence of SEQ ID NO: 35 or a variant thereof, FR-L2 includes or is composed of the amino acid sequence of SEQ ID NO: 36 or a variant thereof, FR-L3 includes or is composed of the amino acid sequence of SEQ ID NO: 37 or a variant thereof, and FR-L4 includes or is composed of the amino acid sequence of SEQ ID NO: 38 or a variant thereof; (3) The framework region FR of the heavy chain variable region includes FR-H1, FR-H2, FR-H3, and FR-H4, among which FR-H1 includes or is composed of the amino acid sequence of SEQ ID NO: 39 or a variant thereof, FR-H2 includes or is composed of the amino acid sequence of SEQ ID NO: 40 or a variant thereof, FR-H3 includes or is composed of the amino acid sequence of SEQ ID NO: 41 or a variant thereof, and FR-H4 includes or is composed of the amino acid sequence of SEQ ID NO: 42 or a variant thereof; The framework region FR of the light chain variable region includes FR-L1, FR-L2, FR-L3, and FR-L4, among which FR-L1 includes or is composed of the amino acid sequence of SEQ ID NO: 43 or a variant thereof, FR-L2 includes or is composed of the amino acid sequence of SEQ ID NO: 44 or a variant thereof, FR-L3 includes or is composed of the amino acid sequence of SEQ ID NO: 45 or a variant thereof, and FR-L4 includes or is composed of the amino acid sequence of SEQ ID NO: 46 or a variant thereof; (4) The framework region FR of the heavy chain variable region includes FR-H1, FR-H2, FR-H3, and FR-H4, of which FR-H1 includes or is composed of the amino acid sequence of SEQ ID NO: 47 or a variant thereof, FR-H2 includes or is composed of the amino acid sequence of SEQ ID NO: 48 or a variant thereof, FR-H3 includes or is composed of the amino acid sequence of SEQ ID NO: 49 or a variant thereof, and FR-H4 includes or is composed of the amino acid sequence of SEQ ID NO: 50 or a variant thereof; The framework region FR of the light chain variable region includes FR-L1, FR-L2, FR-L3, and FR-L4, among which FR-L1 includes or is composed of the amino acid sequence of SEQ ID NO: 51 or a variant thereof, FR-L2 includes or is composed of the amino acid sequence of SEQ ID NO: 52 or a variant thereof, FR-L3 includes or is composed of the amino acid sequence of SEQ ID NO: 53 or a variant thereof, and FR-L4 includes or is composed of the amino acid sequence of SEQ ID NO: 54 or a variant thereof; Therein, the sequence of said variant has at least 80%, preferably at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or 99% homology to the corresponding sequence or has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence.

[0032] 3. The pharmaceutical composition according to item 1 or 2, wherein the antibody that specifically binds to CD47 is (1) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:2 or a variant thereof, or consisting of the above sequence; A light chain variable region comprising or consisting of the amino acid sequence shown in SEQ ID NO:4 or a variant thereof; (2) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 12 or a variant thereof, or consisting of the above sequence; A light chain variable region comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 14 or a variant thereof; (3) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 16 or a variant thereof, or consisting of the above sequence; A light chain variable region comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 18 or a variant thereof; (4) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 20 or a variant thereof, or consisting of the above sequence; A light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 22 or a variant thereof, or comprising the above sequence; Among them, the first protein functional domain of the above anti-PD-1-anti-CTLA4 antibody is: (1) A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 87 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 88 or a variant thereof; (2) A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 129 or a variant thereof; A light chain variable region comprising the sequence shown in SEQ ID NO: 130 or a variant thereof, or composed of the above sequence, The second protein functional domain of the anti-PD-1-anti-CTLA4 antibody is (1) A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 95 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 96 or a variant thereof; (2) A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 133 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 134 or a variant thereof; (3) A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 135 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 136 or a variant thereof; (4) A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 137 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 138 or a variant thereof; (5) A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 131 or a variant thereof; A light chain variable region comprising the sequence shown in SEQ ID NO: 132 or a variant thereof, or consisting of the above sequence, Preferably, the heavy chain amino acid sequence contained in the immunoglobulin of the anti-PD-1-anti-CTLA4 antibody is as shown in SEQ ID NO: 139, and targets PD-1; Among them, the first protein functional domain of the anti-PD-1-anti-VEGFA antibody is (1) A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 103 or a variant thereof; A light chain variable region comprising the sequence shown in SEQ ID NO: 104 or a variant thereof, or consisting of the above sequence, The second protein functional domain of the anti-PD-1-anti-VEGFA antibody is (1) A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 111 (preferably encoded by the nucleotide sequence set forth in SEQ ID NO: 145) or a variant thereof; A light chain variable region comprising the sequence shown in SEQ ID NO: 112 (preferably encoded by the nucleotide sequence shown in SEQ ID NO: 146) or a variant thereof, or composed of the above sequence; Preferably, the heavy chain amino acid sequence contained in the immunoglobulin of the anti-PD-1-anti-VEGFA antibody is as set forth in SEQ ID NO: 140, and targets VEGFA; The anti-PD-1 monoclonal antibody comprises or is composed of a heavy chain variable region set forth in SEQ ID NO: 121 and a light chain variable region set forth in SEQ ID NO: 122; Among them, the above-mentioned variants are amino acid sequences having at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to the corresponding sequence, or having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence.

[0033] 4. The pharmaceutical composition according to any one of items 1 to 3, wherein the antibody that specifically binds to CD47 further comprises a heavy chain constant region and a light chain constant region, and the constant region is derived from a non-murine species, for example, from a human antibody, preferably from human IgG or IgM, more preferably from IgG1; preferably, the heavy chain constant region is an Ig gamma-1 chain C region, ACCESSION: P01857 (SEQ ID NO: 58), or an Ig gamma-4 chain C region, ACCESSION: P01861.1 (SEQ ID NO: 56); the light chain constant region is an Ig kappa chain C region, ACCESSION: P01834 (SEQ ID NO: 57); and preferably, the antibody that specifically binds to CD47 is secreted by hybridoma cell line LT012, deposit number of which is CCTCC NO: 2018135.

[0034] 5. The pharmaceutical composition according to any one of items 1 to 4, wherein the antibody that specifically binds to CD47 and the heavy chain constant region of the immunoglobulin have mutations at any one, two or three positions, i.e., positions 234, 235 and 237, according to the EU numbering system, and the affinity constant of the bispecific antibody for FcγRIIIa and / or C1q is reduced after the mutation compared to before the mutation, preferably the affinity constant is measured using a Fortebio Octet molecular interaction device, Preferably, said antibody that specifically binds to CD47 comprises the mutations L234A and / or L235A, according to the EU numbering system, More preferably, the heavy chain constant region of the immunoglobulin is L234A and L235A, or L234A and G237A, or L235A and G237A, or having one of the combinations of mutations L234A, L235A, and G237A; More preferably, According to the EU numbering system, the heavy chain constant regions of the above immunoglobulins are and further having one of the following combinations of mutations: N297A, D265A, D270A, P238D, L328E, E233D, H268D, P271G, A330R, C226S, C229S, E233P, P331S, S267E, L328F, A330L, M252Y, S254T, T256E, N297Q, P238S, P238A, A327Q, A327G, P329A, K322A, T394D, G236R, G236A, L328R, A330S, P331S, H268A, E318A and K320A.

[0035] 6. The pharmaceutical composition according to any one of items 1 to 5, wherein the antibody that specifically binds to CD47 is (1) a heavy chain represented by SEQ ID NO: 59 and a light chain represented by SEQ ID NO: 60; (2) a heavy chain represented by SEQ ID NO: 61 and a light chain represented by SEQ ID NO: 62; (3) a heavy chain represented by SEQ ID NO: 63 and a light chain represented by SEQ ID NO: 64; (4) a heavy chain represented by SEQ ID NO: 65 and a light chain represented by SEQ ID NO: 66; (5) A heavy chain represented by SEQ ID NO: 67 and a light chain represented by SEQ ID NO: 68, and (6) A heavy chain and a light chain selected from the group consisting of a heavy chain represented by SEQ ID NO: 69 and a light chain represented by SEQ ID NO: 70, or consisting of them; The above anti-PD-1-anti-CTLA4 antibody is A heavy chain represented by SEQ ID NO: 78 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 77) and a light chain represented by SEQ ID NO: 80 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 79) are included, or are composed of them; The above anti-PD-1-anti-VEGFA antibody is The heavy chain represented by SEQ ID NO: 141 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 142) and the light chain represented by SEQ ID NO: 143 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 144) are selected from the group consisting of heavy chain and light chain, The anti-PD-1 monoclonal antibody comprises or consists of a heavy chain and a light chain selected from the group consisting of a heavy chain represented by SEQ ID NO:82 (preferably encoded by the nucleotide sequence represented by SEQ ID NO:81) and a light chain represented by SEQ ID NO:84 (preferably encoded by the nucleotide sequence represented by SEQ ID NO:83).

[0036] 7. The pharmaceutical composition according to any one of items 1 to 6, wherein the antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, Fab / c, a complementarity determining region (CDR) fragment, a single chain antibody (e.g., scFv), a bivalent antibody, or a domain antibody.

[0037] 8. The pharmaceutical composition according to any one of items 1 to 7, wherein the antibody that specifically binds to CD47 is a humanized antibody, a chimeric antibody, or a multispecific antibody (for example, a bispecific antibody).

[0038] 9. The pharmaceutical composition according to any one of items 1 to 8, wherein the antibody that specifically binds to CD47 is about 10 -5 Less than m, e.g., about 10 -6 Less than M, about 10 -7 Less than M, about 10 -8 Less than M, about 10 -9 Less than M or about 10 -10 K less than M or less D An antibody that binds to human CD47 protein with an EC50 of less than about 100 nM, e.g., less than about 10 nM, less than about 1 nM, less than about 0.9 nM, less than about 0.8 nM, less than about 0.7 nM, less than about 0.6 nM, less than about 0.5 nM, less than about 0.4 nM, less than about 0.3 nM, less than about 0.2 nM, less than about 0.1 nM or less.

[0039] 10. The pharmaceutical composition according to any one of items 1 to 9, wherein the antibody that specifically binds to CD47 is in the form of an antibody conjugate comprising the antibody that specifically binds to CD47 or an antigen-binding fragment thereof according to any one of items 1 to 9 and a conjugation moiety that is conjugated to the antibody that specifically binds to CD47 or an antigen-binding fragment thereof, the conjugation moiety being a purification tag (e.g., a His tag), a cytotoxic agent, or a detectable label, preferably a radioisotope, a luminescent substance, a colored substance, an enzyme, or polyethylene glycol, or The antibody that specifically binds to CD47 is in the form of a multispecific antibody, preferably in the form of a bispecific antibody comprising an antibody that specifically binds to CD47 or an antigen-binding fragment thereof described in any one of items 1 to 9 and an antibody or an antigen-binding fragment thereof against another antigen and / or another antigen epitope, or the antibody that specifically binds to CD47 is in the form of a fusion protein comprising the antibody that specifically binds to CD47 or an antigen-binding fragment thereof described in any one of items 1 to 9.

[0040] 11. The pharmaceutical composition according to any one of items 1 to 10, wherein the tumor therapeutic agent is one or more selected from a tyrosine kinase inhibitor, a DNA polymerase inhibitor, an anti-human CD20 antibody, an anti-human PDL-1 antibody, an anti-human PD-1 antibody, an anti-human CTLA-4 antibody, a BCL-2 inhibitor, an anti-human EGFR antibody, an anti-human HER2 antibody, an anti-human HER3 antibody, a cyclin-dependent kinase inhibitor, an anti-human VEGFR2 antibody, an anti-human VEGF antibody, a proteasome inhibitor, an angiogenesis inhibitor, a Rapidly accelerated fibrosarcoma (RAF) inhibitor, an acalabrutinib, a bispecific antibody, and a fusion protein drug; preferably, the tumor therapeutic agent is Cetuximab, Obinutuzumab, or Rituximab; Preferably, the tumor chemotherapeutic drug is one or more selected from alkylating agents, anthracyclines, antimetabolites, antibiotics, plant-derived drugs and / or hormonal drugs, platinum-based drugs (e.g., cisplatin, carboplatin, oxaliplatin), adriamycins, cyclophosphamide, paclitaxel (e.g., albumin-bound paclitaxel, liposomal paclitaxel, docetaxel), etoposide, gemcitabine, pemetrexed, capecitabine, olaparib, rucaparib, niraparib, talazoparib, fuzuloparib, vinblastines, tamoxifen, megestrol, goserelin, asparaginase, fluorouracil antitumor drugs, and Azacitidine, cytarabine, cyclocytidine.

[0041] 12. The pharmaceutical composition according to any one of items 1 to 11, wherein said pharmaceutical composition further comprises a pharma- ceutically acceptable vector and / or excipient.

[0042] 13. The pharmaceutical composition according to any one of items 1 to 12, wherein the mass ratio of component A to component B1, calculated based on the mass of the antibody, is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, or 5:1; the mass ratio of the component A to the component B3 is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, or 5:1; or The mass ratio of the component B2 to the component A is 1:(1 to 1000), preferably 1:(5 to 500), and more preferably 1:(10 to 100). Preferably, component A and component B in the pharmaceutical composition are in a form suitable for administration by intravenous drip, subcutaneous, intradermal, intravenous, intramuscular or intralesional injection.

[0043] 14. A kit, preferably for use in treating a tumor, comprising product A and product B, wherein the product A comprises an antibody or an antigen-binding fragment thereof that specifically binds to CD47 as defined in any one of items 1 to 13; Product B is one or more selected from product B1, product B2 and product B3, product B1 is the bispecific antibody or antigen-binding fragment thereof defined in any one of items 1 to 13 (preferably, when the bispecific antibody is a combination of anti-PD-1-anti-CTLA4 antibody and anti-PD-1-anti-VEGFA antibody, the anti-PD-1-anti-CTLA4 antibody and the anti-PD-1-anti-VEGFA antibody are present in independent packages or in the same package), product B2 is the tumor chemotherapeutic drug defined in any one of items 1 to 13, and product B3 is the anti-PD-1 monoclonal antibody or antigen-binding fragment thereof defined in any one of items 1 to 13, among which product B1, product B2 and product B3 are present in independent packages or in the same package; Preferably, the kit further comprises a product C, the product C being a tumor therapeutic agent as defined in any one of items 1 to 13, and the product C being different from the product B, Preferably, the kit further comprises a product label.

[0044] 15. The kit according to item 14, wherein the mass ratio of product A to product B1, calculated based on the mass of the antibody, is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, or 5:1; The mass ratio of the product A to the product B3 is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, or 5:1; or The unit dose of the tumor chemotherapy drug is 0.1 mg to 100 mg, 0.5 mg to 50 mg, 1 mg to 20 mg, 2 mg to 15 mg, 4 mg to 12 mg, or 8 mg to 12 mg; Preferably, Product A, Product B or Product C in the above kit is in a form suitable for administration by intravenous drip, subcutaneous injection, intradermal injection, intravenous injection, intramuscular injection or intralesional injection.

[0045] 16. A method for treating or preventing a tumor, comprising administering to a subject in need thereof an effective amount of component A and component B as defined in any one of items 1 to 13, preferably said method further comprising administering to a subject in need thereof an effective amount of component C as defined in any one of items 1 to 13, Preferably, the above-mentioned components A, B and C are administered simultaneously or sequentially, more preferably, the above-mentioned components A, B and C are administered before or after surgical treatment, and / or before or after radiation therapy; Preferably, when component B is component B1 and / or component B3, the single administration dose of component A or component B is 0.1 mg to 100 mg, preferably 1 mg to 10 mg, per kilogram of body weight of the subject, or the single administration dose of component A or component B is 10 mg to 1000 mg, preferably 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg, or 200 mg, per kilogram of body weight of the subject; Preferably, the unit dose of component B2 is from 0.1 mg to 100 mg, from 0.5 mg to 50 mg, from 1 mg to 20 mg, from 2 mg to 15 mg, from 4 mg to 12 mg or from 8 mg to 12 mg; Preferably, the drug is administered twice a day to about once every two days, or once every three days, once every four days, once every five days, once every six days, once every ten days, once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks. Preferably, the administration route is intravenous drip, subcutaneous injection, intradermal injection, intravenous injection, intramuscular injection or intralesional injection.

[0046] 17. The pharmaceutical composition according to any one of items 1 to 13, the kit according to item 14 or 15, or the method according to item 16, wherein the tumor is preferably a tumor expressing CD47, and is preferably a cancer, and the cancer includes solid tumors, blood cancers, lymphomas, blastomas, sarcomas, leukemias, or malignant lymphomas, and more preferably squamous cell carcinomas, myelomas, lung cancers, small cell lung cancers, non-small cell lung cancers, squamous cell carcinomas of the head and neck, gliomas (e.g., gliomas, recurrent gliomas), acute myeloid leukemias, and malignant lymphomas. Myeloid leukemia, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Diffuse large B-cell lymphoma, Follicular lymphoma, Acute lymphocytic leukemia, Acute myeloid leukemia, Chronic lymphocytic leukemia, Chronic myeloid leukemia, Primary mediastinal large B-cell lymphoma, Mantle cell lymphoma, Small lymphocytic lymphoma, T-cell / histiocyte-rich large B-cell lymphoma, Multiple myeloma, Myeloid leukemia-1 protein, Relapsed or refractory peripheral T-cell lymphoma, Myelodysplastic syndrome, Anaplastic large cell lymphoma, Mantle cell lymphoma , marginal zone lymphoma, myelofibrosis, polycythemia vera, bone marrow cancer, bone marrow and extramedullary proliferation, invasive systemic mastocytosis, eosinophilia, dermatofibrosarcoma protuberans, chronic eosinophilic leukemia, gastrointestinal cancer, gastric cancer or esophagogastric junction adenocarcinoma, ovarian cancer, liver cancer, lymphocytic leukemia, colorectal cancer, endometrial cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, adenocarcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma, glioblastoma multiforme, bone cancer, Ewing's sarcoma, cervical cancer, nasopharyngeal cancer, brain cancer, bladder cancer, breast cancer, triploidy Includes: generalized negative breast cancer, intestinal cancer, rectal cancer, colorectal cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, clear cell renal cell carcinoma, head and neck cancer, pharyngeal cancer, hepatocellular carcinoma, central nervous system cancer, esophageal cancer, esophageal squamous cell carcinoma, malignant pleural mesothelioma, systemic amyloidosis, lymphocytic lymphoma, myeloproliferative neoplasms, neuroendocrine tumors, Merkel cell carcinoma, testicular and skin cancer, peritoneal cancer, fallopian tube cancer, urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer, and mesothelioma.

[0047] 18. A unit formulation, preferably used for treating a tumor, the unit formulation comprising 1 mg to 10,000 mg (preferably 10 mg to 1,000 mg, more preferably 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg or 200 mg) of component A and component B defined in any one of items 1 to 13, When component B is component B1 and / or component B3, the unit formulation contains 1 mg to 10,000 mg (preferably 1 mg to 1,000 mg, more preferably 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg, 200 mg or 100 mg) of component B as defined in any one of items 1 to 13, When component B is component B2, the above unit dosage form contains 0.1 mg to 100 mg, 0.5 mg to 50 mg, 1 mg to 20 mg, 2 mg to 15 mg, 4 mg to 12 mg, or 8 mg to 12 mg of component B, Preferably, the unit dosage form further comprises one or more components C as defined in any one of items 1 to 13, Among them, the above components A, B and C are packaged separately.

[0048] 19. A single drug dosage unit, preferably for use in the treatment of tumors, comprising 0.1 mg to 10000 mg (preferably 1 mg to 1000 mg, more preferably 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg, 200 mg or 100 mg) of component A and component B as defined in any one of items 1 to 13, When component B is component B1 and / or component B3, the single drug dosage unit contains 0.1 mg to 10,000 mg (preferably 1 mg to 1,000 mg, more preferably 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg, 200 mg or 100 mg) of component B as defined in any one of items 1 to 13, When component B is component B2, the single drug dosage unit contains 0.1 mg to 100 mg, 0.5 mg to 50 mg, 1 mg to 20 mg, 2 mg to 15 mg, 4 mg to 12 mg, or 8 mg to 12 mg of component B.

[0049] In certain embodiments, the tumor chemotherapeutic agent is selected from Azacitidine, Anthracyclines, Cytarabine, Gemcitabine, and Cyclocytidine.

[0050] The anti-human PD-1 antibody is selected from Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Camrelizumab, and Tislelizumab.

[0051] The anti-human CD20 antibody is selected from Rituximab, Obinutuzumab, BCD-132, H-02, B-001, IMM-0306, ACE-1755, IMM-03, JMT-601, TXB-4BC1, and GB-4542.

[0052] The above anti-human EGFR antibodies include cetuximab, panitumumab, necitumumab, nepidermin, nimotuzumab, amivantamab, HS-627, amelimumab, depatuxizumab, FmAb-2, GC-1118A, imgatuzumab, MVC-101, and SC T-200, QL-1203, tomuzotuximab, JMT-101, MCLA-158, QL-1105, SYN-004, MCLA-129, WBP-297, AM-105, BH-2922, BMX-002 , CMAB-017, DF-203, GB-263, JZB-29, SAH-EJ1, SFR-9X0122, UBP-1215, ABX-901, MCLA-125, TXB-4BC2, 111-In-ch806, depatuxizumab Selected from mafodotin, DR-50201, DXL-1218, ENLS-1, FS-101, GI-3000.

[0053] The BCL-2 inhibitor is selected from Venetoclax.

[0054] The above-mentioned HER2 or anti-HER3 antibodies include trastuzumab, trastuzumab emtansine, trastuzumab deruxtecan, margetuximab, pertuzumab, disitamab vedotin, U-31402, ISU-104, SIB-001, 9F7-F11, EV-20Sap, U-31402, ARX-788, BAT-8001, HL-02, TAA-013, trastuzumab duocarmazine, A-166, AU-101, AU-105, BPX-603, ISB-1302, KN-026, MB-103, MRG-002, zanidatamab, zenoc utuzumab, ACE-1702, ALTP-7, B-002, BAT-8001, BAT-1006, BAY-2701439, BTRC-4017A, CAMH-2, cinrebafusp alfa, CT-0508, DP-303c, DX-126262, FS-102, FS-1502, GQ-1001, HS-630, LCB-14, M-802, MBS-301, MT-5 Selected from 111, NJH-395, PF-06804103, SBT-6050, SENL-006, SHRA-1201, SHRA-1811, TT-16, ZW-49, LZM-006, The anti-human VERFR2 antibody is selected from Ramucirumab, AK109, VXM-01, AVI-3207, gentuximab, KD-035, and JY-025.

[0055] The paclitaxel drug is selected from paclitaxel, albumin-bound paclitaxel, liposomal paclitaxel and docetaxel.

[0056] The cyclin-dependent kinase inhibitors include palbociclib, seliciclib, milciclib, lerociclib, abemaciclib, ebvaciclib, ribociclib succinate, trilaciclib, SHR-6390, alvocidib hydrochloride, AT-7519, AZD-4573, BEY-1107, BPI-1178, CT-7001, FCN-437c, FIT-039, NUV-422, PF-07104091, XZP-3287, and zotiraciclib. Selected from citrate, AGM-130, AUR-102, fadraciclib, LY-3405105, HS-10342, ON-123300, QHRD-107, TQ-05510, voruciclib, JS-101, XH-30002, AZ-5576, ETH-155008, JS-104, and RMC-4550.

[0057] The proteasome inhibitor is selected from Bortezomib, Carfilzomib, and Ixazomib.

[0058] The tyrosine kinase inhibitor is selected from anlotinib, acalabrutinib, brigatinib, alectinib hydrochloride, ibrutinib, radotinib dihydrochloride, bosutinib monohydrate, ponatinib hydrochloride, crizotinib, ruxolitinib phosphate, nilotinib hydrochloride hydrate, dasatinib hydrate, and imatinib mesylate.

[0059] The angiogenesis inhibitor antibody drug is selected from bevacizumab, ramucirumab, and ranibizumab.

[0060] The Rapidly accelerated fibrosarcoma (RAF) inhibitor antibody drug is selected from LY3009120, Dabrafenib, Vemurafenib, and Sorafenib.

[0061] The hormone system inhibitor is selected from dexamethasone, tamoxifen, toremifen, flutamide, nilutamide, leuprolide, goserelin, buserelin, aminoglutethimide, and formestane.

[0062] The anti-human PD-1 antibody is selected from Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, and Penpulimab.

[0063] The anti-human PDL-1 antibody is selected from Atezolizumab, Avelumab, Durvalumab, and AK105.

[0064] The anti-human CTLA-4 antibody is selected from ZW25, Ipilimumab, and Tremelimumab.

[0065] The anti-human PD-1 / CTLA-4 bispecific antibody is selected from Cadonilimab, SI-B003, QL1706, XmAb-20717, KN046, MGD019, and MEDI5752.

[0066] The anti-human PD-1 / VEGFA bispecific antibody is selected from AK112 (i.e., VP101(hG1DM)).

[0067] The platinum-based drug is selected from cisplatin (DDP), carboplatin (CBP) and oxaliplatin (L-OHP),

[0068] The anti-human PDL-1 antibody is selected from Avelumab, Atezolizumab, Durvalumab, JS-003, CS-100L, LY-3300054, KD-033, CK-301, CCX-4503, CX-072, KN-035, HRP00052, HRP00049, FAZ-053, GR-1405, KD-005, HLX-20, KL-Al67, CBT-502, STI-A1014, REMD-290, BGB-A333, BCD-135, and MCLA-145O.

[0069] The fusion protein drug is selected from Aflibercept, AVID200, Trebananib, and M7824.

[0070] In an embodiment of the invention, the medicament is in a form suitable for injection, preferably in a form suitable for administration by subcutaneous, intradermal, intravenous, intramuscular or intralesional injection.

[0071] In the present invention, unless otherwise specified, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art.In addition, the cell culture, molecular genetics, nucleic acid chemistry, and immunological laboratory procedures used in the present invention are common procedures widely used in the art.At the same time, in order to better understand the present invention, the following provides definitions and explanations of relevant terms.

[0072] The term "antigen-binding region" as used herein refers to a protein or a portion of a protein that specifically binds to a given antigen. For example, the portion of an antibody that contains amino acid residues that interact with an antigen and confer specificity and affinity to the antibody for the antigen is called the "antigen-binding region". An antigen-binding region generally contains one or more "complementarity-determining regions" ("CDRs"). Some antigen-binding regions further contain one or more "framework" regions (fragment regions, "FRs"). CDRs are amino acid sequences that contribute to the specificity and affinity of antigen binding.

[0073] The term "antibody" as used in the present invention refers to a complete immunoglobulin of any isotype, or an antigen-binding fragment thereof capable of specifically binding to a target antigen in competition with the complete antibody, and includes chimeric antibodies, humanized antibodies, fully humanized antibodies, and bispecific antibodies or antigen-binding fragments thereof. Such an "antibody" is a type of antigen-binding protein. A complete antibody generally comprises at least two full-length heavy chains and two full-length light chains, although in some cases it may comprise fewer chains, for example, naturally occurring antibodies in camelids are antibodies that comprise only heavy chains. An antibody or antigen-binding fragment thereof may be derived from a single source, or may be "chimeric", i.e., different portions of the antibody may be derived from two different sources, as described below. An antibody or antigen-binding fragment thereof may be produced by recombinant DNA technology in a hybridoma, or by enzymatic or chemical cleavage of a complete antibody. Unless otherwise specified, the term "antibody" includes not only antibodies comprising two full-length heavy chains and two full-length light chains, but also derivatives, variants, and fragments thereof.

[0074] The term "antigen-binding fragment" (sometimes abbreviated as fragment) of an "antibody" or "immunoglobulin chain (heavy or light chain)" as used herein includes a portion of an antibody (regardless of how the portion was obtained or synthesized) that lacks some amino acids present in the full-length antibody chain but is capable of specifically binding to an antigen. Such fragments are biologically active because they can specifically bind to a target antigen and compete with other antibodies or antigen-binding fragments thereof to specifically bind to a given epitope. In one aspect, such fragments retain at least one CDR present in the full-length light or heavy chain of the antibody, and in some embodiments include a single heavy and / or light chain or portion thereof. Such biologically active fragments may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Immunofunctional immunoglobulin fragments include, but are not limited to, Fab, Fab', F(ab')2, Fab / c, dAb, Fv, domain antibodies, single chain antibodies, and may be derived from any mammalian source, including, but not limited to, human, mouse, rat, camelid, or rabbit. It is also envisioned that functional portions of the antibodies disclosed herein (e.g., one or more CDRs) can be covalently linked to a second protein or small molecule to generate therapeutic agents that are directed to specific targets in vivo, and thus have bifunctional therapeutic properties or extended serum half-life, including, for example, fusion proteins.

[0075] As used herein, the terms "full antibody chain", "full length antibody", "intact antibody" and "whole antibody" are used interchangeably herein to refer to an antibody having substantially the same structure as a native antibody or having a heavy chain of the Fc region as defined herein.

[0076] The term "light chain" includes a full-length light chain and fragments thereof that contain sufficient variable region sequence to confer binding specificity. A full-length light chain contains the variable region domain V L and constant region domain C LThe light chain variable region domain is at the amino-terminus of the polypeptide. Light chains include kappa chains and lambda chains.

[0077] The term "heavy chain" includes a full-length heavy chain and fragments thereof that contain sufficient variable region sequence to confer binding specificity. A full-length heavy chain includes the variable region domain V H , and three constant region domains C H1 , C H2 , C H3 Includes: V H The domain is at the amino terminus of the polypeptide and is H The domain is located at the carboxy terminus and is C H3 is at the most carboxy-terminus of the polypeptide. The heavy chain may have any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 isoforms), IgA (including IgA1 and IgA2 isoforms), IgM, and IgE.

[0078] The term "Fab fragment" as used herein refers to a fragment that contains one light chain, C H1 and one heavy chain variable region. The heavy chain of a Fab molecule cannot form disulfide bonds with another heavy chain molecule.

[0079] As used herein, the term "Fc" region refers to the C region of an antibody. H1 and C H2 The two heavy chain fragments contain two or more disulfide bonds and a C domain. H3 The domains are held together by hydrophobic interactions.

[0080] The term "Fab' fragment" as used herein refers to a fragment of one light chain and one heavy chain (V) that can form an interchain disulfide bond between the two heavy chains of the two Fab' fragments to form a F(ab')2 molecule. H Domain, C H1 Domain and C H1 and C. H2 (including a portion of the region between the domains).

[0081] The term "F(ab')2 fragment" as used herein refers to a fragment of two light chains and a C(ab')2 fragment that is fragmented to form an interchain disulfide bond between two heavy chains. H1 and C. H2 It contains two heavy chains that contain portions of the constant region between the domains, resulting in an F(ab')2 fragment consisting of two Fab' fragments held together by disulfide bonds between the two heavy chains.

[0082] As used herein, the term "Fv region" comprises the variable regions from the heavy and light chains, but lacks the constant regions.

[0083] The term "Fd" fragment as used herein refers to a V H and C H1 It refers to an antibody fragment composed of domains (Ward et al., Nature 341: 544-546 (1989)).

[0084] As used herein, the term "dAb" fragment refers to a V H It is composed of domains (Ward et al., Nature 341: 544-546(1989)).

[0085] The term "Fab'-SH" as used herein is the present designation for Fab' in which the cysteine ​​residue(s) of the constant domains bear a free thiol group.

[0086] The term "Fab / c" fragment as used in the present invention refers to an antibody decomposition intermediate product formed by digesting immunoglobulin with pepsin, and has the advantages of both Fab and Fc regions, i.e., it has the characteristics of strong diffusion ability and slow metabolic clearance in the body, while maintaining high affinity (Liu Jianjun, Journal of Cellular and Molecular Immunology, 1989(4): 29-29).

[0087] The term "single-chain antibody" as used herein refers to an Fv molecule in which the variable regions of the heavy and light chains are connected by a flexible linker to form a single polypeptide chain (forming the antigen-binding region) (see, for example, Bird et al., Science. 242: 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA. 90: 5879-5883 (1988)). Single-chain antibodies are described in detail in International Patent Application Publication No. WO 88 / 01649 and US Patents US Patent 4,946,778 and US Patent 5,260,203 (the disclosures of the international patent application and US Patents of the above publication numbers are incorporated by reference).

[0088] The term "domain antibody" as used herein refers to an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain, including multivalent or bivalent domain antibodies. H The domains are covalently linked by a peptide linker to generate multivalent domain antibodies (particularly bivalent domain antibodies). H The regions can target homologous or distinct antigens.

[0089] The term "bivalent antigen-binding protein" or "bivalent antibody" as used herein is one that contains two antigen-binding sites. In some cases, the two binding sites have the same antigen specificity. A bivalent antibody may be bispecific.

[0090] The term "multispecific antigen-binding protein" or "multispecific antibody" as used herein is an antigen-binding protein or antibody that targets more than one antigen or epitope.

[0091] The term "bispecific" or "bifunctional" antigen-binding protein or antibody as used in the present invention refers to a hybrid antigen-binding protein or antibody, each of which has two different antigen-binding sites. Bispecific antibodies are multispecific antigen-binding proteins or antibodies, which can be produced in a variety of ways, including but not limited to fusion of hybridomas, linking of Fab' fragments. See, for example, Songsivilai, Lachmann, 1990, Clin. Exp. Immunol. 79: 315-321; Kostelny et al., 1992, J.Immunol. 148: 1547-1553. The two binding sites of a bispecific antigen-binding protein or antibody bind to two different epitopes present on homologous or different protein targets.

[0092] The term "monoclonal antibody" or similar terms as used herein refers to an antibody or a fragment of an antibody that is derived from a series of highly homologous antibody molecules, i.e., a series of antibody molecules that are completely the same except for spontaneously occurring natural mutations. Monoclonal antibodies have high specificity for a single epitope on an antigen. Compared to monoclonal antibodies, polyclonal antibodies generally contain at least two or more different antibodies that generally recognize different epitopes on an antigen. Monoclonal antibodies can generally be obtained using the hybridoma technique first published by Kohler et al. (Nature, 256: 495, 1975), and can also be obtained using recombinant DNA techniques (see, for example, USP 4,816,567).

[0093] The term "humanized antibody" as used in the present invention refers to an antibody or antibody fragment obtained by replacing all or a part of the CDR region of a human immunoglobulin (receptor antibody) with the CDR region of a non-human antibody (donor antibody), where the donor antibody may be a non-human (e.g., mouse, rat or rabbit) antibody having the desired specificity, affinity or reactivity. Furthermore, to further improve or optimize the performance of the antibody, some amino acid residues in the framework region (FR) of the receptor antibody may be replaced with the corresponding amino acid residues of a non-human antibody or with amino acid residues of another antibody. For more details regarding humanized antibodies, see, e.g., Jones et al., Nature, 321: 522-525 (1986); Reichmann et al., Nature, 332: 323-329 (1988); Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992); Clark, Immunol. Today 21: 397-402 (2000).

[0094] The term "epitope" as used in the present invention refers to a site on an antigen that is specifically bound by an immunoglobulin or antibody. "Epitope" is also referred to in the art as "antigenic determinant". An epitope or antigenic determinant generally consists of a chemically active surface group of a molecule, such as an amino acid or a carbohydrate or sugar side chain, and generally has specific three-dimensional structural characteristics and specific charge characteristics. For example, an epitope generally includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or non-consecutive amino acids in a unique spatial conformation, and may be a "linear" epitope or a "conformational" epitope. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, GE Morris, Ed. (1996). In a linear epitope, all of the interaction sites between the protein and the interacting molecule (e.g., an antibody) occur linearly along the primary amino acid sequence of the protein, whereas in a conformational epitope, the interaction sites occur across amino acid residues of the protein that are separated from each other.

[0095] The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms are used for amino acid polymers in which one or more amino acid residues are analogs or mimetics of the corresponding naturally occurring amino acids, as well as for naturally occurring amino acid polymers. The terms also include amino acid polymers that have been modified or phosphorylated, for example, by the addition of carbohydrate residues to form glycoproteins. Polypeptides and proteins can be produced from naturally occurring and non-recombinant cells, or can be produced by genetic engineering or recombinant cells, and include molecules having the amino acid sequence of a naturally occurring protein, or molecules in which one or more amino acids of the naturally occurring sequence have been deleted, added, and / or substituted.

[0096] In some embodiments, the terms "polypeptide" and "protein" specifically include antibodies, such as anti-human CD47 antibodies (also referred to as CD47 antibodies), CD47 binding proteins, or variants thereof (e.g., antibodies or sequences in which one or more amino acids have been deleted, added and / or substituted).

[0097] The term "polypeptide fragment" refers to a polypeptide having an amino-terminal deletion, a carboxy-terminal deletion, and / or an internal deletion compared to the full-length protein. Such fragments may contain modified amino acids compared to the full-length protein. In certain embodiments, the length of the fragment is about 5 to 500 amino acids. For example, the length of the fragment may be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids. Useful polypeptide fragments include immunologically functional fragments of antibodies comprising a binding domain. In the case of human CD47 antibodies, useful fragments include, but are not limited to, CDR regions, variable domains of the heavy or light chains, portions of the antibody chains, or variable domains comprising just two CDRs, and the like.

[0098] A "derivative" of a polypeptide is a polypeptide (e.g., an antigen binding protein or antibody) that has been chemically modified in a manner different from an insertion, deletion, or substitution mutant, such as by the attachment of another chemical moiety, e.g., a PEG-conjugated polypeptide.

[0099] In the present invention, unless otherwise specified, the alphabet before the position number indicates the amino acid before mutation, and the alphabet after the position number indicates the amino acid after mutation.

[0100] In some embodiments of the invention, there is a disulfide bond between the VH and VL of the single chain antibody. Methods for introducing disulfide bonds between the VH and VL of an antibody are well known in the art, and are described, for example, in U.S. Pat. No. 5,747,654; Rajagopal et al., Prot. Engin. 10(1997)1453-1459; Reiter et al., Nat. Biotechnol. 14(1996)1239-1245; Reiter et al., Protein Engineering 8(1995)1323-1331; Webber et al., Molecular Immunology 32(1995)249-258; Reiter et al., Immunity 2(1995)281-287; Reiter et al., JBC 269(1994)18327-18331; Reiter et al., Inter. J. of Cancer 58 (1994) 142-149, or Reiter et. al, Cancer Res. 54 (1994) 2714-2718, which are incorporated herein by reference.

[0101] The term "specifically binds" as used herein refers to a non-random binding reaction between two molecules, e.g., a reaction between an antibody and an antigen to which it is directed. In one embodiment, an antibody that specifically binds to an antigen (or has specificity for an antigen) is one in which the antibody binds to the antigen at a concentration of about 10 -5 Less than m, e.g., about 10 -6 Less than M, about 10 -7 Less than M, about 10 -8 Less than M, about 10 -9 Less than M, about 10 -10 Affinity (K D ) to bind to the antigen.

[0102] The term "K" as used herein D " refers to the dissociation equilibrium constant of a particular antibody-antigen interaction and is used to describe the binding affinity between an antibody and an antigen. Among the parameters of molecular binding kinetics measurements, K DThe value is the dissociation equilibrium constant, which in the field of antibody drugs is a parameter that indicates the strength of affinity between the antibody being measured and the target antigen molecule, and is calculated as KD=kdis / kon. The smaller the dissociation equilibrium constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and antigen. kon is the binding rate constant, which is the rate at which the antigen-antibody complex is formed; the smaller kon is, the faster the binding rate between the antibody and antigen. kdis is the dissociation rate constant, which is the rate at which the antibody dissociates from the antigen-antibody complex; the smaller kdis is, the slower the rate at which the antibody leaves the antigen and the more stable the antibody-antigen binding is. In general, antibodies have a molecular weight of about 10 -5 Less than m, e.g., about 10 -6 Less than M, about 10 -7 Less than M, about 10 -8 Less than M, about 10 -9 Less than M, about 10 -10 The dissociation equilibrium constant (K D ) to an antigen (e.g., L1 protein) and measured, for example, using surface plasmon resonance (SPR) in a BIACORE instrument or a Fortebio molecular interaction instrument.

[0103] As used herein, the term "monoclonal antibody" or similar terms have the same meaning and are used interchangeably, the term "polyclonal antibody" or similar terms have the same meaning and are used interchangeably, and the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. In addition, in the present invention, amino acids are usually represented by abbreviations or abbreviation words well known in the art. For example, alanine can be represented by A or Ala.

[0104] As used herein, the terms "hybridoma" and "hybridoma cell line" are used interchangeably, and when "hybridoma" and "hybridoma cell line" are referred to, subclones and progeny of the hybridoma are also included.

[0105] As used herein, the terms "percent sequence identity" and "percent sequence homology" are used interchangeably.

[0106] The terms "similarity" or "sequence similarity" and "identity" as used herein refer to the relationship between the sequences of two or more protein or polypeptide molecules, as determined, for example, by matching and comparing sequences. "Percent identity" refers to the percentage of identical residues between amino acids in the compared molecules, and can be calculated from the size of the smallest molecule being compared. To perform these calculations, gaps (if any) must be resolved during matching by a specific mathematical model or computer program (i.e., algorithm). When applied to polypeptides, the term "substantial identity" refers to two peptide sequences sharing at least 70%, 75% or 80% sequence identity, at least 90% or 95% sequence identity, or at least 97%, 98% or 99% sequence identity when optimally aligned, for example, using the programs GAP or BESTFIT, with default gap weights provided in the programs. In some cases, residue positions that are not identical differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced by another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophilicity). In general, a conservative amino acid substitution does not substantially change the functional properties of a protein. When two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity can be adjusted upwards to correct for the conservative substitution. Methods for making such adjustments are well known to those of skill in the art. See, for example, Pearson, Methods Mol. Biol. 243: 307-31 (1994). Examples of groups of amino acids with side chains with similar chemical properties include: 1) aliphatic hydroxy side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic hydroxy side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid; and 7) sulfur-containing side chains: cysteine ​​and methionine.For example, conservative amino acids substitution combinations are: valine-leucine-isoleucine-glycine-alanine, phenylalanine-tyrosine, threonine-serine, lysine-arginine, glutamic acid-aspartic acid, and asparagine-glutamine.

[0107] Optionally, a conservative substitution is any change that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al., Science 256: 1443-45 (1992), which is incorporated herein by reference. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.

[0108] Generally, sequence analysis software is used to measure sequence identity of polypeptides. Protein analysis software matches sequences using similarity measures that assign different substitutions, deletions, and other modifications (including conservative amino acid substitutions). For example, GCG includes programs such as "Gap" and "Bestfit", which can be used (using the default parameters specified in the program) to measure sequence homology or sequence identity between closely related polypeptides (e.g., homologous polypeptides from different species) or between a wild-type protein and its mutant protein. See, for example, GCG Version 6.1 (University of Wisconsin, WI). Also, polypeptide sequences may be compared using FASTA, using default or recommended parameters, and refer to the match of the best overlap region between the subject sequence and the search sequence and the percent sequence identity provided in GCG Version 6.10 FASTA (e.g., FASTA2, FASTA3) (Pearson, Methods Enzymol. 183: 63-98 (1990): Pearson, Methods Mol. Biol. 132: 185-219 (2000)). When comparing sequences against a database containing a large number of sequences from various species, another preferred algorithm is the computer program BLAST, in particular blastp or tblastn (using the default parameters provided in the program). See, for example, Altschul et al., Mol. Biol. 215: 403-410 (1990): Altschul et al., Nucleic Acids Res. 25: 3389-402 (1997).

[0109] The term "pharmacologically acceptable vector and / or excipient" as used herein refers to a vector and / or excipient that is pharmacologically and / or physiologically compatible with the subject and active ingredient, which is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusting agents, surfactants, adjuvants, and ionic strength enhancing agents. For example, pH adjusting agents include, but are not limited to, phosphate buffers, surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants such as Tween-80, and ionic strength enhancing agents include, but are not limited to, sodium chloride.

[0110] As used herein, the term "effective amount" refers to an amount sufficient to achieve or at least partially achieve a desired effect. For example, an effective amount for preventing a disease (e.g., a tumor) refers to an amount sufficient to prevent, inhibit or delay the onset of the disease (e.g., a tumor), and an effective amount for treating a disease refers to an amount sufficient to cure or at least partially inhibit the disease and its complications in a patient having the disease.

[0111] The term "single drug dosage unit" refers to a single drug dosage form (e.g., an injectable (e.g., disposed in an ampoule)) containing the anti-CD47 antibody of the present invention and a combination therapeutic agent (e.g., a bispecific antibody, an anti-PD-1 monoclonal antibody, and / or a tumor chemotherapeutic agent) administered to a subject at a predetermined administration time (preferably on a per kg basis of the subject's body weight). In certain embodiments of the present invention, the administration regimen includes, for example, administering the single drug dosage unit at a dosing frequency of twice daily to about once every two days, or once every three days, once every four days, once every five days, once every six days, once every ten days, or once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, or once every six weeks.

[0112] In the present invention, unless otherwise specified, the above terms "first" (e.g., first protein functional domain, first connected fragment) and "second" (e.g., second protein functional domain, second connected fragment) are used merely for the sake of clarity in terms of indication or expression, and do not have any meaning of indicating a typical order.

[0113] A "therapeutically effective amount" or "therapeutically effective dose" of a drug or therapeutic agent is any amount of the drug, when used alone or in combination with another therapeutic agent, that prevents the onset of a disease or promotes the resolution of a disease in a subject, as evidenced by a reduction in the severity of symptoms of the disease, an increase in the frequency and duration of symptom-free periods of the disease, or a prevention of impairment or disability due to the affliction of the disease. A variety of methods known to those of skill in the art can be used to assess the ability of a therapeutic agent to promote resolution of a disease, for example, measuring the activity of the agent in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays.

[0114] A "prophylactically effective amount" of a drug refers to any amount of drug that, when administered alone or in combination with an anti-tumor agent to a subject at risk of developing cancer (e.g., a subject with a pre-aggravated disease state) or at risk of cancer recurrence, inhibits the onset or recurrence of cancer. In some embodiments, a prophylactically effective amount completely prevents the onset or recurrence of cancer. "Inhibiting" the onset or recurrence of cancer refers to reducing the likelihood that cancer will develop or recur, or completely preventing the onset or recurrence of cancer.

[0115] Compared with the prior art, the present invention has the following advantages:

[0116] The anti-CD47 monoclonal antibody of the present invention can specifically bind to CD47, thereby effectively blocking the binding of SIRPα to CD47 and promoting the phagocytosis of tumor cells by macrophages, and can exhibit superior anti-tumor activity when used in combination with immune checkpoint inhibitors or other drugs. [Brief description of the drawings]

[0117] [Figure 1] Phagocytosis index of HPMM phagocytosis against Raji cells mediated by the combination of 6F7H1L1 (hG4) and Rituximab. [Diagram 2] Phagocytosis index of HPMM phagocytosis against HL-60 cells mediated by the combination of 6F7H1L1 (hG4) and Azacitidine. [Diagram 3] Promoting immune cell activation by combining 6F7H1L1(hG4) with a PD-1 / CTLA-4 bispecific antibody. [Figure 4] The combination of 6F7H1L1 (hG4) and PD-1 antibody promotes immune cell responses against human lung adenocarcinoma cell line A549 cells. [Diagram 5] The combination of 6F7H1L1 (hG4) and PD-1 antibody promotes immune cell responses against human ovarian cancer cell line SK-OV-3 cells. [Figure 6] The combination of 6F7H1L1 (hG4) and PD-1 antibody promotes immune cell responses against human prostate cancer LNCAP cells. [Figure 7] Phagocytosis index of HPMM phagocytosis against HT-29 cells mediated by the combination of 6F7H1L1 (hG4) and Cetuximab. [Figure 8] Phagocytosis index of HPMM phagocytosis against Raji cells mediated by the combination of 6F7H1L1 (hG4) and Obinutuzumab. [Figure 9] Effect of the combination of 6F7H1L1 (hG4) and the anti-PD-1-anti-CTLA-4 bispecific antibody Cadonilimab on the BALB / c-hPD1 / hSIRPα mouse CT26-hCD47 tumor model. [Figure 10]Changes in body weight in the BALB / c-hPD1 / hSIRPα mouse CT26-hCD47 tumor model in response to the combination of 6F7H1L1 (hG4) and the anti-PD-1-anti-CTLA-4 bispecific antibody Cadonilimab. [Figure 11] Effect of the combination of 6F7H1L1 (hG4) and anti-PD-1-anti-VEGFA bispecific antibody VP101 (hG1DM) on the SCID Beige mouse MDA-MB-231 tumor model. [Figure 12] Change in body weight in a SCID Beige mouse MDA-MB-231 tumor model in response to the combination of 6F7H1L1 (hG4) and the anti-PD-1-anti-VEGFA bispecific antibody VP101 (hG1DM).

[0118] Instructions for deposit of biological material:

[0119] The hybridoma cell line LT012 has been kept in the China Center for Typical Culture Collection (CCTCC) since June 21, 2018, with the deposit number CTCCC NO: C2018135, and the deposit address is Wuhan University, Wuhan, China, with the postal code 430072. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0120] Hereinafter, the embodiments of the present invention will be described in detail with reference to examples. Those skilled in the art should understand that the following examples are merely for illustrating the present invention and do not limit the scope of the present invention. If no specific techniques or conditions are specified in the examples, they will be performed according to the techniques or conditions described in the literature in the field (for example, see Sambrook J, et al., Molecular Cloning: A Laboratory Manual, 3rd Ed, Cold Spring Harbor Laboratory Press) or according to the product instructions. If no manufacturer is specified, the reagents or equipment used may be commercially available general products.

[0121] The BALB / C mice used in the following examples of the present invention are purchased from Guangdong Medical Experimental Animal Center.

[0122] The isotype control antibodies (i.e., hIgG1, hIgG4) used in the following experimental examples of the present invention are all antibodies targeting human anti-egg lysosome (HEL), and the variable region sequences of these antibodies are derived from the literature by Acierno et al., Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies (Acierno et al., J Mol Biol. 2007; 374(1): 130-46), of which the heavy chain variable region sequence is as shown in SEQ ID NO: 75 and the light chain variable region sequence is as shown in SEQ ID NO: 76). In the constant region fragment of hIgG1, the heavy chain constant region is Ig gamma-1 chain C region, ACCESSION: P01857, and the light chain constant region is Ig kappa chain C region, ACCESSION: P01834. In the hIgG4 heavy chain constant region, the Ig gamma-4 chain C region, ACCESSION: P01857, and the light chain constant region is Ig kappa chain C region, ACCESSION: P01834. The heavy chain constant region is the Ig kappa chain C region, ACCESSION:P01861.1, and the S228P mutation that improves stability has been introduced. The light chain constant region is the Ig kappa chain C region, ACCESSION:P01834. Both hIgG1 and hIgG4 are produced in the laboratory of Zhongshan Yasufang Biopharmaceutical Co., Ltd.

[0123] The peripheral blood mononuclear cells (PBMCs) used in the following experimental examples of the present invention were isolated and prepared by Zhongshan Yasufang Bio-Pharmaceutical Co., Ltd. Peripheral blood PBMCs from healthy subjects were isolated according to the instructions for the Ficoll-Paque™ Plus reagent separation solution, and the isolated PBMCs were counted and frozen for storage. The isolation and extraction of peripheral blood and PBMCs from healthy subjects were all performed with the informed consent of the donors.

[0124] Human peripheral monocyte derived macrophages (HPMMs) used in the following experimental examples of the present invention are derived from PBMCs.

[0125] The light and heavy chain sequences of the anti-PD-1 / CTLA-4 bispecific antibody Cadonilimab (i.e., CP004 (hG1TM) antibody) used in the following experimental examples of the present invention are derived from WHO Drug Information, Proposed INN: List 124 (WHO Drug Information, 2020; 34(4): 947-949, the heavy chain sequence is as set forth in SEQ ID NO: 78, the nucleotide sequence encoding it is as set forth in SEQ ID NO: 77, and the light chain sequence is as set forth in SEQ ID NO: 80, the nucleotide sequence encoding it is as set forth in SEQ ID NO: 79). The light and heavy chain sequences of the anti-PD-1 antibody (Penpulimab antibody) are derived from WHO Drug Information, Proposed INN: List 123 (WHO Drug Information, 2020; 34(2): 375-376, the heavy chain sequence is as set forth in SEQ ID NO: 82, the nucleotide sequence encoding it is as set forth in SEQ ID NO: 81, the light chain sequence is as set forth in SEQ ID NO: 84, and the nucleotide sequence encoding it is as set forth in SEQ ID NO: 83). The heavy chain sequence of the anti-PD-1-anti-VEGFA antibody is as set forth in SEQ ID NO: 141 (encoded by the nucleotide sequence set forth in SEQ ID NO: 142), and the light chain sequence is as set forth in SEQ ID NO: 143 (encoded by the nucleotide sequence set forth in SEQ ID NO: 144).

[0126] The preparation methods of Cadonilimab, anti-PD-1-anti-VEGFA antibody, and Penpulimab are as follows: The DNA sequence (including constant and variable regions) of the gene encoding the heavy chain of the candidate antibody and the DNA sequence (including constant and variable regions) of the gene encoding the light chain are cloned into the pUC57simple (provided by GenScript) vector to obtain pUC57simple-H and pUC57simple-L plasmids, respectively. The above plasmids are digested (HindIII and EcoRI), and the heavy and light chains recovered by electrophoresis are subcloned into the expression vector pcDNA3.1 (purchased from Invitrogen), and the recombinant plasmids are extracted and co-transfected into 293F cells with the combination of pcDNA3.1-H + pcDNA3.1-L. After 7 days of cell culture, the culture solution is centrifuged at high speed, the supernatant is concentrated, and then loaded onto a HiTrap MabSelect SuRe column and purified using a protein purification liquid chromatography system (AKTA Purifier 10, GE). The purified sample (i.e., antibody Cadonilimab) is added to reducing protein electrophoresis buffer and non-reducing protein electrophoresis buffer, boiled, and then detected by SDS-PAGE electrophoresis, and screened to verify whether the protein matches the theoretical size, thus obtaining a purified antibody. EXAMPLES

[0127] Example 1: Preparation of anti-human CD47 antibody 6F7

[0128] 1. Preparation of Hybridoma Cell Line 6F7 The antigen used in the preparation of anti-CD47 antibody by hybridoma cell line 6F7 was CD47 IgV TEV-His (containing the fusion protein of human CD47 mature peptide at position 19-141 of Genbank ID: NP 942088.1 and TEV (amino acid sequence is ENLYFQG, SEQ ID NO: 74)-his tag, synthesized by Zhongshan Kangfang Bio-Pharmaceutical Co., Ltd.) and 3T3-CD47 cells (NIH / 3T3, manufacturer: ATCC, product number: CRL-1658, based on NIH / 3T3, the above human CD47 mature peptide was transfected into the cells to establish a 3T3-CD47 stable expression system). Spleen cells from immunized mice were fused with mouse myeloma cells to produce hybridoma cells, and the hybridoma cells were screened by indirect ELISA using CD47 IgV TEV-His and 3T3-CD47 cells as antigens, respectively, to obtain hybridoma cells capable of secreting antibodies that specifically bind to CD47. The hybridoma cells screened by ELISA were screened by competitive ELISA for a hybridoma cell line capable of secreting a monoclonal antibody that binds to human CD47 IgV TEV-His in competition with the receptor human SIRPαECD-hFc-Biotin (wherein SIRPαECD represents the extracellular domain of SIRPα, which is located at positions 31-373 of the protein GenBank accession number NP_542970.1, and hFc is human IgG Fc purification tag, specifically, the Ig gamma-1 chain C region, which is located at positions 114-330 of Genbank ID: P01857), and a stable hybridoma cell line was obtained by limiting dilution. The hybridoma cell line was named hybridoma cell line LT012, and the monoclonal antibody secreted by it was named 6F7.

[0129] The hybridoma cell line LT012 (CD47-6F7) has been deposited in the China Center for Typical Culture Collection (CCTCC) since June 21, 2018, with the deposit number CTCCC NO: C2018135 and the deposit address is Wuhan University, Wuhan, China, with the postal code 430072.

[0130] 2. Preparation of Anti-CD47 Antibody 6F7

[0131] The LT011, LT012, and LT015 cell lines prepared as described above were each cultured in Chemical Defined Medium (CD medium containing 1% penicillin-streptomycin in a cell incubator at 5% CO2 and 37°C). After 7 days, the cell culture supernatant was collected and subjected to high-speed centrifugation, vacuum filtration using a microporous membrane, and purification using a HiTrap protein A HP column to obtain antibody 6F7.

[0132] Example 2: Sequence analysis of anti-CD47 antibody 6F7

[0133] mRNA was extracted from the LT012 cell line cultured in Example 1 according to the method of the cultured cell / bacteria total RNA extraction kit (Tiangen, product number DP430).

[0134] cDNA was synthesized and PCR amplified according to the instructions in the Invitrogen SuperScript® III First-Strand Synthesis System for RT-PCR kit.

[0135] TA cloning was performed directly on the PCR amplification product, and the specific procedure was performed by referring to the instructions for the pEASY-T1 Cloning Kit (Transgen CT101).

[0136] The product of TA cloning was directly sequenced, and the sequencing results were as follows:

[0137] The nucleic acid sequence of the heavy chain variable region is as shown in SEQ ID NO:1 and is 351 bp in length.

[0138] The amino acid sequence encoding it is as shown in SEQ ID NO:2 and is 117 aa in length, the sequence of its heavy chain CDR1 is as shown in SEQ ID NO:5, the sequence of its heavy chain CDR2 is as shown in SEQ ID NO:6 and the sequence of its heavy chain CDR3 is as shown in SEQ ID NO:7.

[0139] The nucleic acid sequence of the light chain variable region is as shown in SEQ ID NO:3 and is 321 bp in length.

[0140] The amino acid sequence encoding it is as shown in SEQ ID NO:4 and is 107 aa in length, the sequence of its light chain CDR1 is as shown in SEQ ID NO:8, the sequence of its light chain CDR2 is as shown in SEQ ID NO:9 and the sequence of its light chain CDR3 is as shown in SEQ ID NO:10.

[0141] Example 3: Design and preparation of the light and heavy chains of anti-human CD47 humanized antibodies 6F7H1L1 (hG4), 6F7H2L2 (hG4), and 6F7H3L3 (hG4)

[0142] 1. Design of the light and heavy chains of anti-human CD47 humanized antibodies 6F7H1L1 (hG4), 6F7H2L2 (hG4), and 6F7H3L3 (hG4)

[0143] Based on the three-dimensional crystal structure of human CD47 protein (Hage T, Reinemer P, Sebald W. Crystals of a 1:1 complex between human interleukin-4 and the extracellular domain of its receptor alpha chain. Eur J Biochem. 1998; 258(2): 831-6) and the sequence of antibody 6F7 obtained in Example 2, an antibody model was simulated in a computer, and mutations were designed based on the model to obtain variable region sequences of antibodies 6F7H1L1, 6F7H2L2, and 6F7H3L3 (the antibody constant region sequences were derived from the NCBI database, the heavy chain constant region sequence was Ig gamma-4 chain C region, ACCESSION: P01861.1, and further, an S228P mutation was introduced to improve stability, and the light chain constant region was Ig kappa chain C region, ACCESSION: P01834). The complete antibodies including the constant regions are designated 6F7H1L1(hG4), 6F7H2L2(hG4) and 6F7H3L3(hG4), respectively.

[0144] The designed variable region sequences were as follows:

[0145] (1) Heavy chain variable region and light chain variable region sequences of humanized monoclonal antibody 6F7H1L1

[0146] The nucleic acid sequence of the heavy chain variable region is as shown in SEQ ID NO:11 and is 351 bp in length.

[0147] The amino acid sequence encoding it is as shown in SEQ ID NO: 12 and is 117 aa in length, the sequence of its heavy chain CDR1 is as shown in SEQ ID NO: 5, the sequence of its heavy chain CDR2 is as shown in SEQ ID NO: 6 and the sequence of its heavy chain CDR3 is as shown in SEQ ID NO: 7.

[0148] The nucleic acid sequence of the light chain variable region is as shown in SEQ ID NO: 13 and is 321 bp in length.

[0149] The amino acid sequence encoding it is as shown in SEQ ID NO: 14 and is 107 aa in length, the sequence of its light chain CDR1 is as shown in SEQ ID NO: 8, the sequence of its light chain CDR2 is as shown in SEQ ID NO: 9 and the sequence of its light chain CDR3 is as shown in SEQ ID NO: 10.

[0150] (2) Heavy chain variable region and light chain variable region sequences of humanized monoclonal antibody 6F7H2L2

[0151] The nucleic acid sequence of the heavy chain variable region is as shown in SEQ ID NO: 15 and is 351 bp in length.

[0152] The amino acid sequence encoding it is as shown in SEQ ID NO: 16 and is 117 aa in length, the sequence of its heavy chain CDR1 is as shown in SEQ ID NO: 5, the sequence of its heavy chain CDR2 is as shown in SEQ ID NO: 6 and the sequence of its heavy chain CDR3 is as shown in SEQ ID NO: 7.

[0153] The nucleic acid sequence of the light chain variable region is as shown in SEQ ID NO: 17 and is 321 bp in length.

[0154] The amino acid sequence encoding it is as shown in SEQ ID NO: 18 and is 107 aa in length, the sequence of its light chain CDR1 is as shown in SEQ ID NO: 8, the sequence of its light chain CDR2 is as shown in SEQ ID NO: 9 and the sequence of its light chain CDR3 is as shown in SEQ ID NO: 10.

[0155] (3) Heavy chain variable region and light chain variable region sequences of humanized monoclonal antibody 6F7H3L3

[0156] The nucleic acid sequence of the heavy chain variable region is as shown in SEQ ID NO: 19 and is 351 bp in length.

[0157] The amino acid sequence encoding it is as shown in SEQ ID NO:20 and is 117 aa in length, the sequence of its heavy chain CDR1 is as shown in SEQ ID NO:5, the sequence of its heavy chain CDR2 is as shown in SEQ ID NO:6 and the sequence of its heavy chain CDR3 is as shown in SEQ ID NO:7.

[0158] The nucleic acid sequence of the light chain variable region is as shown in SEQ ID NO:21 and is 321 bp in length.

[0159] The amino acid sequence encoding it is as shown in SEQ ID NO:22 and is 107 aa in length, the sequence of its light chain CDR1 is as shown in SEQ ID NO:8, the sequence of its light chain CDR2 is as shown in SEQ ID NO:9 and the sequence of its light chain CDR3 is as shown in SEQ ID NO:10.

[0160] 2. Preparation of humanized antibodies 6F7H1L1(hG4), 6F7H2L2(hG4) and 6F7H3L3(hG4)

[0161] The heavy chain cDNA and light chain cDNA of 6F7H1L1 (hG4), the heavy chain cDNA and light chain cDNA of 6F7H2L2 (hG4), and the heavy chain cDNA and light chain cDNA of 6F7H3L3 (hG4) were each cloned into a pUC57simple (provided by GenScript) vector to obtain pUC57simple-6F7H1 (hG4), pUC57simple-6F7L1, pUC57simple-6F7H2 (hG4), pUC57simple-6F7L2, pUC57simple-6F7H3 (hG4), and pUC57simple-6F7L3, respectively. According to the standard techniques introduced in "Molecular Cloning: A Laboratory Manual, 2nd Ed", the synthesized full-length heavy and light chain genes were digested with EcoRI and HindIII, and then subcloned into the expression vector pcDNA3.1 by digestion with restriction enzymes (EcoRI and HindIII) to obtain expression plasmids pcDNA3.1-6F7H1(hG4), pcDNA3.1-6F7L1, pcDNA3.1-6F7H2(hG4), pcDNA3.1-6F7L2, pcDNA3.1-6F7H3(hG4), and pcDNA3.1-6F7L3. Furthermore, the heavy and light chain genes of the recombinant expression plasmids were subjected to sequencing analysis. Next, gene combinations (pcDNA3.1-6F7H1(hG4) / pcDNA3.1-6F7L1, pcDNA3.1-6F7H2(hG4) / pcDNA3.1-6F7L2, and pcDNA3.1-6F7H3(hG4) / pcDNA3.1-6F7L3) were designed for the recombinant plasmids containing the corresponding light and heavy chains, and each was co-transfected into 293F cells, after which the culture medium was harvested and purified. After correct sequencing and verification, endotoxin-free expression plasmids were prepared and the plasmids were transiently transfected into HEK293 cells to express the antibodies, and after 7 days, the cell culture medium was harvested and affinity purified with a Protein A column (MabSelect SURE(GE)) to obtain humanized antibodies.

[0162] Example 4: Design and preparation of the light and heavy chains of anti-human CD47 humanized antibodies 6F7H1L1(G1M), 6F7H2L2(G1M) and 6F7H3L3(G1M)

[0163] 1. Design of the light and heavy chains of anti-human CD47 humanized antibodies 6F7H1L1(G1), 6F7H2L2(G1), and 6F7H3L3(G1)

[0164] Based on the three-dimensional crystal structure of human CD47 protein (Hage T, Reinemer P, Sebald W. Crystals of a 1:1 complex between human interleukin-4 and the extracellular domain of its receptor alpha chain. Eur J Biochem. 1998; 258(2): 831-6) and the sequence of antibody 6F7 obtained in Example 2, an antibody model was simulated in a computer, and mutations were designed based on the model to obtain variable region sequences of antibodies 6F7H1L1, 6F7H2L2, and 6F7H3L3 (the antibody constant region sequences were derived from the NCBI database, the heavy chain constant region was the Ig gamma-1 chain C region, ACCESSION: P01857, and the light chain constant region was the Ig kappa chain C region, ACCESSION: P01857). region and ACCESSION: P01834), the humanized antibodies were named 6F7H1L1(G1), 6F7H2L2(G1) and 6F7H3L3(G1), respectively, to distinguish them from the humanized antibodies of Example 3 above.

[0165] The variable region sequences of the humanized antibodies 6F7H1L1(G1), 6F7H2L2(G1) and 6F7H3L3(G1) designed in this example were identical to the variable region sequences of 6F7H1L1(hG4), 6F7H2L2(hG4) and 6F7H3L3(hG4) in Example 3.

[0166] 2. Preparation of humanized antibodies 6F7H1L1(G1), 6F7H2L2(G1), and 6F7H3L3(G1)

[0167] The inventors obtained new humanized antibodies by introducing a point mutation from leucine to alanine (L234A) at position 234 (EU numbering) and a point mutation from leucine to alanine (L235A) at position 235 (EU numbering) in the heavy chain hinge region of 6F7H1L1(G1), 6F7H2L2(G1), and 6F7H3L3(G1), which they named 6F7H1L1(G1M), 6F7H2L2(G1M), and 6F7H3L3(G1M), respectively.

[0168] The heavy chain cDNA and light chain cDNA of 6F7H1L1(G1M), the heavy chain cDNA and light chain cDNA of 6F7H2L2(G1M), and the heavy chain cDNA and light chain cDNA of 6F7H3L3(G1M) were each cloned into a pUC57simple (provided by GenScript) vector to obtain pUC57simple-6F7H1(G1M), pUC57simple-6F7L1, pUC57simple-6F7H2(G1M), pUC57simple-6F7L2, pUC57simple-6F7H3(G1M), and pUC57simple-6F7L3, respectively. According to the standard techniques introduced in "Molecular Cloning: A Laboratory Manual, 2nd Ed", the synthesized full-length heavy and light chain genes were digested with EcoRI and HindIII, and then subcloned into the expression vector pcDNA3.1 by digestion with restriction enzymes (EcoRI and HindIII) to obtain expression plasmids pcDNA3.1-6F7H1(G1M), pcDNA3.1-6F7L1, pcDNA3.1-6F7H2(G1M), pcDNA3.1-6F7L2, pcDNA3.1-6F7H3(G1M), and pcDNA3.1-6F7L3. Furthermore, the heavy and light chain genes of the recombinant expression plasmids were subjected to sequencing analysis. Next, gene combinations (pcDNA3.1-6F7H1(G1M) / pcDNA3.1-6F7L1, pcDNA3.1-6F7H2(G1M) / pcDNA3.1-6F7L2, pcDNA3.1-6F7H3(G1M) / -pcDNA3.1-6F7L3) were designed for the recombinant plasmids containing the corresponding light and heavy chains, and each was co-transfected into 293F cells, after which the culture medium was harvested and purified. After correct sequencing and verification, endotoxin-free expression plasmids were prepared and the plasmids were transiently transfected into HEK293 cells to express the antibodies, and after 7 days, the cell culture medium was harvested and affinity purified with a Protein A column (MabSelect SURE(GE)) to obtain humanized antibodies.

[0169] Example 5: Promotion of macrophage phagocytosis of tumor cells by combined use of 6F7H1L1 (hG4) and Rituximab or Azacitidine

[0170] Experimental materials: Azacitidine (purchased from Baxter Oncology GmbH), Hu5F9-G4 (manufactured by Zhongshan Yasufang Biopharmaceutical Co., Ltd.), Raji cells (Shanghai Institute of the Chinese Academy of Sciences), HL-60 cells (ATCC), RPMI 1640 (Gibco, product number: 22400-105), trypsin (0.25% Typsin-EDTA (1x)) (Gibco, product number: 25200072), fetal bovine serum (FBS) (Excell bio, product number: FSP500), fluorescent dye carboxyfluorescein diacetate N-succinimidyl ester (56-carboxyfluorescein diacetatesuccinimidyl ester, CFSE) (Biolegend, product number: 423801), recombinant human macrophage colony-stimulating factor (human M-CSF) (peprotech, product number: 300-25), APC-labeled anti-human CD11c antibody (Biolegend, product number: 301614), isotype control (human IgG4) (manufactured by Zhongshan Yasufumi Bio-Pharmaceutical Co., Ltd.), Rituximab (Roche), BSA (manufacturer: Sigma, product number: V900933-1KG), Ficoll paque plus (manufacturer: GE, product number: 17-1440-02).

[0171] Preparation of human peripheral monocyte derived macrophages (HPMM): HPMM were induced from PBMC. Cryopreserved PBMC were thawed in the usual manner and left in an incubator overnight. The next day, PBMC were collected and centrifuged at 170 × g for 5 min, resuspended in 1640 medium containing 2% FBS, and left in an incubator for 2 h. The supernatant was removed, washed twice with PBS, and induced for 7 days by adding 1640 complete medium (containing 10% FBS) and 100 ng / mL human M-CSF. On days 3 and 5, the medium was replaced and 100 ng / mL human M-CSF was added. On day 7, HPMM that had completed induction were collected, centrifuged at 170 × g for 5 min, the supernatant was discarded, and resuspended in 1640 complete medium (containing 10% FBS) to a cell density of 1 × 10 6 The concentration was adjusted to 10,000 cells / mL and dispensed into 1.5 mL EP tubes for use.

[0172] 1.6F7H1L1(hG4) and Rituximab combination enhances macrophage phagocytosis of tumor cells

[0173] Experimental Objective: This study was conducted to compare the in vitro cell biology of 6F7H1L1(hG4) in combination with Rituximab and 6F7H1L1(hG4) alone in the antibody dependent cellular phagocytosis (ADCP) mediated by human Burkitt's lymphoma cell line Raji. The test system used HPMM as effector cells and Burkitt's lymphoma cell line Raji as target cells.

[0174] Test method: Logarithmic growth phase Raji cells were harvested in the usual way, centrifuged at 170 × g for 5 min, resuspended, and washed once with PBS. Raji cells were resuspended in CFSE (2.5 μM) (staining density: 1 × 10 7The staining was stopped by adding 6 mL of 1640 complete medium, centrifuged at 170 × g for 5 min, the supernatant was discarded, and the staining was resuspended in 1 mL of 1640 complete medium and incubated in an incubator for 10 min. Each antibody was diluted with 1640 complete medium to the working concentration shown, and an isotype control antibody (anti-HEL antibody, human IgG4) was designed at the same time. The antibody and target cells were added in a 1:1 volume to the corresponding EP tube containing HPMM (final volume was 100 μL, effector cell to target cell ratio was 5 × 10 4 :1.5×10 5 The cells were resuspended and mixed uniformly, incubated in a 37°C incubator for 2 h, added 800 μL of 1% PBSA (PBS containing 1% BSA) solution at room temperature to each tube, centrifuged at 1200×g for 5 min, discarded the supernatant, washed once with 800 μL of 1% PBSA, added 100 μL / sample of APC-labeled anti-human CD11c antibody (Biolegend lot:371506) (diluted 400 times with 1% PBSA) to the corresponding sample for labeling, and incubated on ice for 40 min. Added 800 μL of 1% PBSA to each tube, centrifuged at 1200×g for 5 min, discarded the supernatant, washed once with 800 μL of 1% PBSA, resuspended in 200 μL of 1% PBSA to each tube, and loaded into a FACS Calibur flow cytometer for detection. The loading system was designed to detect APC-CD11b macrophages. + Macrophages that are positive and undergo phagocytosis are APC-CD11b + CFSE + The ratio of double positive cells to APC positive cells was used as the phagocytic index to evaluate the ADCP activity mediated by the antibody. The ADCP activity of each group was calculated using the following formula and expressed as P%:

[0175]

number

[0176] Experimental results: In this example, HPMM was used as the effector cell and Raji was used as the target cell to detect the antibody-mediated phagocytosis (ADCP) by the combination of 6F7H1L1 (hG4) and Rituximab. The result is Error! Source not found. The phagocytosis index of Rituximab and 6F7H1L1 (hG4) is obviously higher than that of the blank control and the isotype control (human IgG4), indicating that Rituximab and 6F7H1L1 (hG4) have ADCP activity. The phagocytosis index of the combination of 6F7H1L1 (hG4) and Rituximab is obviously higher than that of 6F7H1L1 (hG4), indicating that the combination of 6F7H1L1 (hG4) and Rituximab has higher ADCP activity than either alone.

[0177] 2.6F7H1L1(hG4) and Azacitidine Combined Therapy Enhances Macrophage Phagocytosis of Tumor Cells

[0178] Experimental Objective: This experiment was to compare the antibody-dependent cellular phagocytosis ADCP mediated by acute myelocytic leukemia (AML) cell line HL-60 with the combination of 6F7H1L1(hG4) and Azacitidine in vitro cell biology. The test system used HPMM as effector cells and AML cell line HL-60 treated with different concentrations of Azacitidine as target cells.

[0179] Test method: HL-60 was harvested normally and plated in a 6-well plate, with each well containing 4 × 10 5The medium was 1640 complete / 2 mL, and different concentrations of azacitidine were added (working concentrations were 3 μM and 1 μM). A blank HL-60 group was also added and incubated in an incubator for 24 h. The following day, the HL-60 cells after incubation with the reagent and the blank HL-60 cells were collected, centrifuged at 170 × g for 5 min, resuspended, counted to measure viability, and washed once with PBS. CFSE was diluted to 2.5 μM in PBS, and the HL-60 cells were resuspended in the diluted CFSE (staining density: 1 × 10 7 The cells were incubated in an incubator for 20 min, staining was stopped by adding 6 mL of 1640 complete medium (containing 10% FBS), centrifuged at 170 × g for 5 min, the supernatant was discarded, and 1 mL of 1640 complete medium was added to resuspend the cells, incubated in an incubator for 10 min, and each antibody was diluted in 1640 complete medium to 20 and 2 μg / mL (working concentrations were 10 and 1 μg / mL), and an isotype control antibody (anti-HEL antibody, human IgG4) was designed at the same time. The antibodies and target cells were added to the corresponding conical bottom plate containing HPMM (final volume was 100 μL, effector cell to target cell ratio was 5 × 10 4 :1.5×10 5 The cells were resuspended and mixed uniformly, incubated in a 37°C incubator for 2 h, 150 μL of 1% PBSA (PBS containing 1% BSA) solution at room temperature was added to each well, centrifuged at 1000×g for 5 min, the supernatant was discarded, washed once with 200 μL of 1% PBSA, and 100 μL / sample of APC-labeled anti-human CD11c antibody (diluted 400 times with 1% PBSA) was added to the corresponding sample for labeling, and incubated on ice for 40 min. 150 μL of 1% PBSA was added to each well, centrifuged at 1000×g for 5 min, the supernatant was discarded, washed once with 200 μL of 1% PBSA, resuspended in 200 μL of 1% PBSA, and loaded into a FACS Calibur flow cytometer for detection. Macrophages were APC-CD11b in the loading system. + Macrophages that are positive and undergo phagocytosis are APC-CD11b +CFSE + The results were double positive. The ratio of double positive cells to APC positive cells was used as the phagocytic index to evaluate the ADCP activity mediated by the antibody. The ADCP activity of each group was calculated using the formula (1) in this example and expressed as P%.

[0180] Experimental results: This test used Hu5F9-G4 targeting CD47 as a positive control antibody, HPMM as effector cells, and HL-60 as target cells to detect the ADCP activity of 6F7H1L1 (hG4) and Azacitidine in combination. The results are shown in Error! Source not found. The phagocytosis index of Azacitidine, 6F7H1L1 (hG4), and Hu5F9-G4 is obviously higher than that of the blank control and isotype control (human IgG4), indicating that Azacitidine, 6F7H1L1 (hG4), and Hu5F9-G4 have phagocytosis-promoting activity. The phagocytosis index of 6F7H1L1(hG4), Hu5F9-G4 and Azacitidine combination was obviously higher than that of single antibodies, indicating that 6F7H1L1(hG4), Hu5F9-G4 and Azacitidine combination had higher ADCP activity than single antibodies. Compared with the control antibody Hu5F9-G4 for the same target, the ADCP activity of 6F7H1L1(hG4) and Azacitidine combination was equivalent to that of Hu5F9-G4 and Azacitidine combination.

[0181] Example 6: Promotion of immune cell activation by combined use of 6F7H1L1 (hG4) with PD-1 / CTLA-4 bispecific antibody and PD-1 antibody

[0182] Experimental materials: PBMC cells (isolated and prepared by Zhongshan Kangfang Biomedical Co., Ltd.), A549 cells (Cell Center, Chinese Academy of Sciences, product number: KCB-200434YJ), SK-VO-3 cells (ATCC, product number: HTB-77), HL-60 cells (ATCC, product number: CCL-240), LNCAP (Cell Resources Center, Shanghai Institute of Life Sciences, Chinese Academy of Sciences), Raji-PDL1 cells (constructed by Zhongshan Kangfang Biomedical Co., Ltd., constructed PDL-1 lentiviral vector by conventional method, packaged the virus, infected Raji cells, and screened with blasticidin to obtain Raji-PDL1), DMEM medium (Gibco, product number: 11995-081), Trypsin-EDTA (0.25%), phenol red (Gibco, product number: 25200072), RPMI 1640 medium (Gibco, product number: 22400-105), Blasticidin (Gibco, product number: R210-01), FBS (Excell bio, product number: FSP500), SEB (Staphylococcus aureus enterotoxin antigen) (dianotech, product number: S010201), MMC (Mitomycin C) (Stressmarq, product number: SIH-246), Ficoll-Paque™ PLUS (manufacturer: GE Healthcare, product number: 17-1440-02), human IL-2 ELISA KIT (Dakewe, product number: 1110202), human IFN-γ ELISA KIT (Dakewe, product number: 1110002), isotype control (human IgG1 (Anti-HEL-isotype control)).

[0183] 1. Promoting immune cell activation by combining 6F7H1L1(hG4) with a PD-1 / CTLA-4 bispecific antibody

[0184] Experimental Objective: This study aims to compare the in vitro cell biology activity of 6F7H1L1 (hG4) in combination with PD-1 / CTLA-4 bispecific antibody (Cadonilimab) with 6F7H1L1 (hG4) alone in inducing immune cell responses against human Burkitt's lymphoma cell line Raji-PDL1 cells that overexpress human PDL-1.

[0185] Experimental method: Raji-PDL1 cells were routinely cultured in 1640+10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Raji-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. PBMCs activated with SEB for 2 days and Raji-PDL1 cells treated with MMC were harvested, washed twice with PBS, resuspended in 1640+10% FBS complete medium and counted. Both Raji-PDL1 and PBMCs were 1×10 5 Cells were seeded in a 96-well plate at 10 cells / well, and diluted antibodies were added according to the experimental design. The mixture was mixed evenly and placed in an incubator at 37°C and 5% CO2 for 3 days. After 3 days, the cell culture supernatant was collected and IL-2 and IFN-γ were detected according to the instructions of the ELISA KIT (Dakewe Biotech Co., Ltd.). The experimental medium was 10% FBS+1640.

[0186] Experimental results: The results are shown in Figure 3. Compared with 6F7H1L1 (hG4) alone or PD-1 / CTLA-4 bispecific antibody alone, it can significantly stimulate IFN-γ secretion in PBMC cells. The combination of 6F7H1L1 (hG4) and PD-1 / CTLA-4 bispecific antibody showed better activity than either alone, i.e., it more significantly enhanced the immune response of immune cells against human Burkitt's lymphoma cell line Raji-PDL1 cells.

[0187] 2. Promoting immune cell activation by combining 6F7H1L1(hG4) with PD-1 antibody

[0188] (1) Combination of 6F7H1L1 (hG4) and PD-1 antibody enhances immune cell responses against human lung adenocarcinoma cell line A549 cells

[0189] Objective: This study aims to compare the induction of immune cell responses against Raji-PDL1 cells and human lung adenocarcinoma cell line A549 cells by the combination of 6F7H1L1 (hG4) and PD-1 antibody (Penpulimab) and 6F7H1L1 (hG4) alone in vitro cell biology.

[0190] Experimental method: Raji-PDL1 cells were routinely cultured in 1640+10% FBS complete medium, and A549 cells were routinely cultured in DMEM+10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Raji-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. PBMCs activated with SEB for 2 days and Raji-PDL1 cells treated with MMC were harvested, washed twice with PBS, resuspended in 1640+10% FBS complete medium and counted. Both Raji-PDL1 and PBMCs were counted at 1 × 10 5 Harvest logarithmic-phase A549 cells by seeding them into a 96-well plate at 5 x 10 cells / well and culture A549 cells at 5 x 10 4 Cells were seeded in a 96-well plate at 10 cells / well, and diluted antibodies were added according to the experimental design. The mixture was mixed evenly and placed in an incubator at 37°C and 5% CO2 for 3 days. After 3 days, the cell culture supernatant was collected and IL-2 and IFN-γ were detected according to the ELISA KIT instructions. The experimental medium was 10% FBS+1640.

[0191] Experimental results: The results are shown in Figure 4. Compared with 6F7H1L1 (hG4) alone or PD-1 antibody alone, it can significantly stimulate the secretion of IFN-γ in PBMC cells. The combination of 6F7H1L1 (hG4) and PD-1 antibody showed better activity than either alone, that is, it more significantly enhanced the immune response of immune cells against human lung adenocarcinoma cell line A549 cells.

[0192] (2) Combination of 6F7H1L1 (hG4) and PD-1 antibody enhances immune cell responses against human ovarian cancer cell line SK-OV-3 cells

[0193] Objective of the experiment: This study aims to compare the induction of immune cell responses against Raji-PDL1 cells and human ovarian cancer cell line SK-OV-3 cells by the combination of 6F7H1L1 (hG4) and PD-1 antibody (Penpulimab) and 6F7H1L1 (hG4) alone in vitro cell biology.

[0194] Experimental method: Raji-PDL1 cells were routinely cultured in 1640+10% FBS complete medium, and SK-OV-3 cells were routinely cultured in McCoy's 5A (Modified) Medium+10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Raji-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. PBMCs activated with SEB for 2 days and Raji-PDL1 cells treated with MMC were harvested, washed twice with PBS, resuspended in 1640+10% FBS complete medium and counted. Both Raji-PDL1 and PBMCs were counted at 1 × 10 5 Harvest logarithmic-phase SK-OV-3 cells by seeding them into a 96-well plate at 5 x 10 cells / well and culture SK-OV-3 cells at 5 x 10 4 Cells were seeded in a 96-well plate at 10 cells / well, and diluted antibodies were added according to the experimental design. The mixture was mixed evenly and placed in an incubator at 37°C and 5% CO2 for 3 days. After 3 days, the cell culture supernatant was collected and IL-2 and IFN-γ were detected according to the ELISA KIT instructions. The experimental medium was 10% FBS+1640.

[0195] Experimental results: The results are shown in Figure 5. Compared with 6F7H1L1 (hG4) alone or PD-1 antibody alone, it can significantly stimulate IL-2 secretion of PBMC cells, and the combination of 6F7H1L1 (hG4) and PD-1 antibody showed better activity than either alone, that is, it more significantly enhanced the immune response of immune cells against human ovarian cancer cell line SK-OV-3 cells.

[0196] (3) Combination of 6F7H1L1 (hG4) and PD-1 antibody enhances immune cell responses against human prostate cancer LNCAP cells

[0197] Objective of the experiment: This experiment aims to compare the induction of immune cell responses against Raji-PDL1 cells and human prostate cancer LNCAP cells by the combination of 6F7H1L1 (hG4) and PD-1 antibody (Penpulimab) and 6F7H1L1 (hG4) alone in vitro cell biology.

[0198] Experimental method: Raji-PDL1 cells were routinely cultured in 1640+10% FBS complete medium, and LNCAP cells were routinely cultured in RPMI-1640+10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Raji-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. PBMCs activated with SEB for 2 days and Raji-PDL1 cells treated with MMC were harvested, washed twice with PBS, resuspended in 1640+10% FBS complete medium and counted. Both Raji-PDL1 and PBMCs were counted at 1 × 10 5 Harvest logarithmic-phase LNCAP cells by seeding them into 96-well plates at 5 x 10 cells / well and culture LNCAP cells at 5 x 10 4 Cells were seeded in a 96-well plate at 10 cells / well, and diluted antibodies were added according to the experimental design. The mixture was mixed evenly and placed in an incubator at 37°C and 5% CO2 for 3 days. After 3 days, the cell culture supernatant was collected and IL-2 and IFN-γ were detected according to the ELISA KIT instructions. The experimental medium was 10% FBS+1640.

[0199] Experimental results: The results are shown in Figure 6. Compared with 6F7H1L1 (hG4) alone or PD-1 antibody alone, it could significantly stimulate IL-2 secretion from PBMC cells, and the combination of 6F7H1L1 (hG4) and PD-1 antibody showed better activity than either alone, that is, it more significantly enhanced the immune response of immune cells against LNCAP cells, a human prostate cancer cell.

[0200] Example 7: Promotion of macrophage phagocytosis of tumor cells by combined use of 6F7H1L1 (hG4) and Cetuximab

[0201] Thawed PBMCs (Zhongshan Kangfang Bio-Pharmaceutical Co., Ltd., lot: 20200521-E) were incubated overnight in 1640 complete medium + 10% FBS (Excell bio, product number: FSP500, lot number: 11I025), and the next day, the medium was replaced with 1640 complete medium + 2% FBS and incubated for 2 h. After discarding the supernatant, the medium was washed twice with PBS and added to an incubator (90% 1640 + 10% FBS + M-CSF-100 ng / mL) to induce human macrophages (HPMM, Zhongshan Kangfang Bio-Pharmaceutical Co., Ltd.). The medium was replaced and reagents were added on the 3rd and 5th days, and the experiment was performed on the 7th day of induction.

[0202] HT-29 cells (Cell Resource Center, Shanghai Institute of Life Sciences, Chinese Academy of Sciences, product number: TCHu103) were harvested normally, centrifuged at 170×g for 5 min, resuspended, counted to determine viability, and washed once with PBS. CFSE (Biolegend, product number: 423801) was diluted to 2.5 μM in PBS, and the cells were resuspended with the appropriate amount of diluted CFSE (staining density: 10 million cells / mL), incubated in an incubator for 20 min, added 6 mL of 1640 complete medium (containing 10% FBS) to stop the staining, centrifuged at 170×g for 5 min, discarded the supernatant, added 1 mL of 1640 complete medium, incubated in an incubator for 10 min, resuspended, counted, and adjusted for cell number.

[0203] 6F7H1L1 (hG4) and Cetuximab antibodies (Zhongshan Kangfang Bio-Pharmaceutical Co., Ltd., Lot No.: 20200917) were diluted to the designated concentrations with 1640 complete medium, and an isotype control antibody was designed. Human macrophages were collected, centrifuged at 7170×g for 5 min, the supernatant was discarded, counted, transferred to a 1.5 mL EP tube, centrifuged at 1200×g for 5 min, the supernatant was discarded, the tumor cell + antibody suspension (50 μL each) was added to the 1.5 mL EP tube containing the macrophages, resuspended and mixed uniformly, and incubated in a 37°C incubator for 2 h. 800 μL of 1% PBSA at room temperature was added to each tube, centrifuged at 1200×g for 5 min, the supernatant was discarded, and washed once with 800 μL of PBSA. APC anti-mouse / human CD11b was added at 100 μL / sample. Antibody (diluted 500-fold in PBSA) (Biolegend, product number: 101212, concentration: 0.2 mg / mL) was added to the corresponding samples, mixed uniformly, and incubated on ice for 40 min. 800 μL of 1% PBSA was added to each tube, centrifuged at 1200 × g for 5 min, the supernatant was discarded, each tube was washed once with 800 μL of PBSA, each tube was resuspended in 200 μL of 1% PBSA, and transferred to tubes for flow cytometry and loading.

[0204] Experimental results: In this example, HPMM was used as effector cells and HT29 was used as target cells to detect antibody-mediated phagocytosis (ADCP) by the combination of 6F7H1L1 (hG4) and Cetuximab. The results are shown in Figure 7, and the phagocytosis index of Cetuximab and 6F7H1L1 (hG4) is obviously higher than that of the blank control and the isotype control (human IgG4), indicating that Cetuximab and 6F7H1L1 (hG4) have ADCP activity. The phagocytosis index of the combination of 6F7H1L1 (hG4) and Cetuximab is obviously higher than that of 6F7H1L1 (hG4), indicating that the combination of 6F7H1L1 (hG4) and Cetuximab has higher ADCP activity than either alone.

[0205] Example 8: Promotion of macrophage phagocytosis of tumor cells by combined use of 6F7H1L1 (hG4) and Obinutuzumab

[0206] Thawed PBMCs (manufactured by Zhongshan Kangfang Biopharmaceutical Co., Ltd., lot: 20201126-G) were incubated overnight in 1640 complete medium + 10% FBS (Excell bio, product number: FSP500, lot number: 11I025), and the next day, the medium was replaced with 1640 complete medium + 2% FBS and incubated for 2 h. After discarding the supernatant, the medium was washed twice with PBS and added to an incubator (90% 1640 + 10% FBS + M-CSF-100 ng / mL) to induce human macrophages (HPMMs). On the 3rd and 5th days, the medium was replaced and reagents were added, and the experiment was performed on the 7th day of induction.

[0207] Raji cells (purchased from ATCC) were harvested normally and washed once with PBS. CFSE was diluted to 2.5 μM with PBS, the cells were resuspended in the appropriate amount of diluted CFSE (staining density: 10 million cells / mL), incubated in an incubator for 20 min, 6 mL of 1640 complete medium (containing 10% FBS) was added to stop the staining, centrifuged at 170 × g for 5 min, the supernatant was discarded, 1 mL of 1640 complete medium was added, incubated in an incubator for 10 min, the cell number was adjusted to 3 million / mL, antibodies were diluted to the desired concentration with 1640 complete medium, isotype control antibodies were designed, macrophages were harvested, centrifuged at 170 × g for 5 min, the cell number was adjusted to 1 million / mL, transferred to a 96-well conical bottom plate, and centrifuged at 750 × g for 5 min. The wells were centrifuged for 1 min, the supernatant discarded, the tumor cell + antibody suspension was added to the 96-well conical bottom plate containing the macrophages, resuspended and mixed uniformly, and incubated in a 37°C incubator for 2 h. 150 μL of 1% PBSA at room temperature was added to each well and centrifuged at 750×g for 5 min. The supernatant was discarded, the wells were washed once with 200 μL PBSA, 100 μL / sample of APC anti-mouse / human CD11b antibody (diluted 500-fold in PBSA) was added to the corresponding sample, mixed uniformly, incubated on ice for 40 min, 150 μL of 1% PBSA was added to each well and centrifuged at 750×g for 5 min. The supernatant was discarded, each well was washed once with 200 μL PBSA, each tube was resuspended in 200 μL 1% PBSA, and the tubes were transferred to flow cytometry tubes for loading.

[0208] Experimental results: In this example, HPMM was used as effector cells and Raji was used as target cells to detect antibody-mediated phagocytosis (ADCP) by the combination of 6F7H1L1 (hG4) and Obinutuzumab. The results are shown in Figure 8, and the phagocytosis index of Obinutuzumab and 6F7H1L1 (hG4) is obviously higher than that of the blank control and isotype control (human IgG4, human IgG1), indicating that Obinutuzumab and 6F7H1L1 (hG4) have ADCP activity. The phagocytosis index of the combination of 6F7H1L1 (hG4) and Obinutuzumab is higher than that of 6F7H1L1 (hG4), indicating that the combination of 6F7H1L1 (hG4) and Obinutuzumab has higher ADCP activity than either alone.

[0209] Example 9: Effective tumor treatment with the combination of 6F7H1L1 (hG4) and anti-PD-1-anti-CTLA-4 bispecific antibodies

[0210] To detect the in vivo antitumor activity of the combination of 6F7H1L1 (hG4) antibody and anti-PD-1-anti-CTLA-4 bispecific antibody Cadonilimab, CT26-hCD47 cells (mouse colon cancer cells, purchased from Jiangsu Jiaxing Pharmaceutical Co., Ltd.) were first subcutaneously inoculated into 6.43- to 8.43-week-old female BALB / c-hPD1 / hSIRPα mice (purchased from Jiangsu Jiaxing Pharmaceutical Co., Ltd.), with the average tumor volume ranging from 80 mm to 120 mm. 3 When the tumor volume reached 1000 mg / kg, the mice were randomly divided into 4 groups, with 6 mice per group. The day of grouping was designated as D0, and administration began on the day of grouping, D0. The administration method for the combined administration group was to prepare the drugs separately and administer them before and after (there is no specific requirement for the administration order and interval time, and one drug is administered after another drug). The modeling and specific administration method are shown in Table 1. After administration, the length and width of the tumors in each group were measured, and the tumor volume was calculated. An independent sample t-test (SPSS 17.0) was performed, with *P<0.05 and **P<0.01.

[0211] [Table 1]

[0212] The results are shown in Figure 9. As can be seen from the results, compared with the isotype control antibody hIgG4, both the 6F7H1L1 (hG4) antibody and the PD-1 / CTLA-4 bispecific antibody Cadonilimab could effectively inhibit the growth of mouse tumors, and the 6F7H1L1 (hG4) + Cadonilimab combination group showed a combined antitumor effect in the model, and the tumor inhibition of the combination was superior to that of the test drug alone group.

[0213] Furthermore, as shown in FIG. 10, the tumor-bearing mice had good tolerance to the test drugs 6F7H1L1 (hG4) and Cadonilimab, both administered alone and in combination, and there was no effect on the body weight of the tumor-bearing mice in each group.

[0214] Example 10: Effective tumor treatment with the combination of 6F7H1L1 (hG4) antibody and anti-PD-1-anti-VEGFA bispecific antibody

[0215] To detect the in vivo antitumor activity of the combination of 6F7H1L1 (hG4) antibody and anti-PD-1-anti-VEGFA bispecific antibody VP101 (hG1DM), MDA-MB-231 cells (purchased from ATCC) were first subcutaneously inoculated into 5- to 7-week-old SCID Beige mice (purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.) until the average tumor volume reached 120-150 mm. 3 When the tumor volume reached 1000 mg / kg, the mice were randomly divided into 4 groups, with 6 mice per group. The day of grouping was defined as D0, and the administration began on D0, the day of grouping, and the mice were intraperitoneally injected with activated PBMCs. The administration method for the combined administration group was to prepare the drugs separately and administer them before and after (there is no specific requirement for the administration order and interval time, and one drug is administered after another drug). The modeling and specific administration method are shown in Table 2. After administration, the length and width of the tumors in each group were measured, and the tumor volume was calculated. One-way ANOVA (Bonferroni post-hoc test) was performed, with *P<0.05 and **P<0.01.

[0216] [Table 2]

[0217] The results are shown in Figure 11. As can be seen from the results, compared with the isotype control group, both 6F7H1L1 (hG4) and VP101 (hG1DM) can effectively inhibit the growth of mouse tumors, and the 6F7H1L1 (hG4) + VP101 (hG1DM) combination group showed a combined antitumor effect in the model, and the tumor inhibition of the combination was superior to that of the test drug alone group.

[0218] Furthermore, as shown in FIG. 12, the tumor-bearing mice tolerated the test drugs 6F7H1L1 (hG4) and VP101 (hG1DM) well, either alone or in combination, and there was no effect on the body weight of the tumor-bearing mice in each group.

[0219] Although the embodiments of the present invention have been described in detail above, the present invention is not limited to the above examples, and a person skilled in the art may make various equivalent modifications or replacements without departing from the spirit of the present invention, and these equivalent modifications or replacements are also included in the scope limited by the claims of this application.

[0220] Sequence Listing:

[0221] SEQ ID NO:1: Nucleotide sequence of the heavy chain variable region of 6F7 CAGGTGCAGCTGCAGCAGCCAGGAGCAGAGCTGGTGAGGCCAGGAGCATCCGTGAAGCTGTCTTGTAAGGCCAGCGGCTACACCTTCACATCCTATTGGATGAACTGGGTGAAGCAGAGGCCTGGACAGGGACTGGAGTGGATCGGCATGATCGACCCAAGCGATTCCGAGACCC ACAACAATCAGATGTTTAAGGACAAGGCCACCCTGACAGTGGATAAGAGCTCCAATACCGCCTACATGCACCTGTCTAGCCTGACATCTGAGGACAGCGCCGTGTATCACTGCGCCCGGCTGTACAGATGGTATTTTGACGTGTGGGGAGCAGGAACCACAGTGACCGTGTCCTCT

[0222] SEQ ID NO:2: Amino acid sequence of the heavy chain variable region of 6F7 QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWMNWVKQRPGQGLEWIGMIDPSDSETHNNQMFKDKATLTVDKSSNTAYMHLSSLTSEDSAVYHCARLYRWYFDVWGAGTTVTVSS

[0223] SEQ ID NO:3: Nucleotide sequence of the light chain variable region of 6F7 AACATCGTGATGACCCAGTCCCCCAAGTCTATGAGCATGTCCCTGGGCGAGAGGGTGACCCTGTCCTGTAAGGCCTCTGAGATCGTGGGCACATACGTGTCTTGGTTTCAGCAGAAGCCACACCAGAGCCCCAAGCTGCTGATCTACGGCGCCTCCAATC GGTATACAGGCGTGCCTGACAGATTCACCGGCTCTGGCAGCGCCACAGACTTCACCCTGACAATCTCTAACGTGCAGGCCGAGGACCTGGCCGATTATCACTGCGGCCAGAGCTACAATTTCCCTTATACCTTTGGCGGCGGCACAAAGCTGGAGATCAAG

[0224] SEQ ID NO: 4: Amino acid sequence of the light chain variable region of 6F7 NIVMTQSPKSMSMSLGERVTLSCKASEIVGTYVSWFQQKPHQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISNVQAEDLADYHCGQSYNFPYTFGGGTKLEIK

[0225] SEQ ID NO: 5 HCDR1 of CDR 6F7 GYTFTSYW

[0226] SEQ ID NO: 6 HCDR2 of CDR 6F7 IDPSDSET

[0227] SEQ ID NO: 7 HCDR3 of CDR of F7 ARLYRWYFDV

[0228] SEQ ID NO: 8 LCDR1 of CDR of 6F7 EIVGTY

[0229] SEQ ID NO: 9 LCDR2 of CDR of 6F7 GAS

[0230] SEQ ID NO: 10 LCDR3 of CDR of 6F7 GQSYNFPYT

[0231] SEQ ID NO: 11 Nucleotide sequence of the heavy chain variable region of 6F7H1 CAGGTGCAGCTGGTGCAGAGCGGAGCAGAGGTGGTGAAGCCAGGAGCCTCTGTGAAGCTGAGCTGTAAGGCCTCCGGCTACACCTTCACAAGCTATTGGATGAACTGGGTGCGGCAGAGACCAGGACAGGGACTGGAGTGGATCGGAATGATCGACCCTTCCGATTCTGAGACCC ACAATGCCCAGAAGTTTCAGGGCAAGGCCACCCTGACAGTGGACAAGAGCACCTCCACAGCCTACATGCACCTGAGCTCCCTGCGGTCCGAGGACACAGCCGTGTACTATTGCGCCAGGCTGTACCGCTGGTATTTTGACGTGTGGGGAGCAGGAACCACAGTGACCGTGTCTAGC

[0232] SEQ ID NO: 12 Amino acid sequence of the heavy chain variable region of 6F7H1 QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMNWVRQRPGQGLEWIGMIDPSDSETHNAQKFQGKATLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGTTVTVSS

[0233] SEQ ID NO: 13 Nucleotide sequence of the light chain variable region of 6F7L1 AACATCGTGATGACCCAGTCCCCAGCCACAATGTCTATGAGCCCAGGAGAGAGGGTGACCCTGTCCTGTAGAGCCTCTGAGATCGTGGGCACATACGTGTCTTGGTTTCAGCAGAAGCCAGGACAGGCACCTAGGCTGCTGATCTACGGAGCAAGCAACA GGTATACCGGAGTGCCAGCACGCTTCTCCGGCTCTGGCAGCGGCACAGACTTTACCCTGACAATCAGCTCCGTGCAGCTGAGGACCTGGCCGATTATCACTGCGGCCAGTCTTACAATTTCCCATATACCTTTGGCGGCGGCACAAAGCTGGAGATCAAG

[0234] SEQ ID NO: 14: Amino acid sequence of the light chain variable region of 6F7L1 NIVMTQSPATMSMSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRYTGVPARFSGSGSGTDFTLTISSVQPEDLADYHCGQSYNFPYTFGGGTKLEIK

[0235] SEQ ID NO: 15 Nucleotide sequence of the heavy chain variable region of 6F7H2 CAGGTGCAGCTGGTGCAGAGCGGAGCAGAGGTGGTGAAGCCAGGAGCCTCTGTGAAGGTGAGCTGTAAGGCCTCCGGCTACACCTTCACATCCTATTGGATGAACTGGGTGCGGCAGAGACCAGGACAGGGACTGGAGTGGATCGGAATCATCGACCCTTCCGATTCTGAGACCT CTAATGCCCAGAAGTTTCAGGGCCGGGTGACCCTGACAGTGGACAAGAGCACCTCCACAGCCTACATGCACCTGAGCTCCCTGAGGAGCGAGGACACAGCCGTGTACTATTGCGCCAGGCTGTACCGCTGGTATTTTGACGTGTGGGGAGCAGGAACCACAGTGACCGTGTCTAGC

[0236] SEQ ID NO: 16: Amino acid sequence of the heavy chain variable region of 6F7H2 QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYWMNWVRQRPGQGLEWIGIIDPSDSETSNAQKFQGRVTLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGTTVTVSS

[0237] SEQ ID NO: 17 Nucleotide sequence of the light chain variable region of 6F7L2 AACATCGTGATGACCCAGTCCCCAGCCACACTGTCTCTGAGCCCAGGAGAGAGGGTGACCCTGTCCTGTAGAGCCTCTGAGATCGTGGGCACATACGTGTCTTGGTTTCAGCAGAAGCCAGGACAGGCACCTAGGCTGCTGATCTATGGCGCCAGCAACA GGGCAACCGGCATCCCCGCACGCTTCTCCGGCTCTGGCAGCGGCACAGACTTTACCCTGACAATCAGCTCCCTGCAGCTGAGGACCTGGCCGATTACTATTGCGGCCAGTCTTACAATTTCCCATATACCTTTGGCGGCGGCACAAAGCTGGAGATCAAG

[0238] SEQ ID NO: 18: Amino acid sequence of the light chain variable region of 6F7L2 NIVMTQSPATLLSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRATGIPARFSGSGSGTDFTLTISSLQPEDLADYYCGQSYNFPYTFGGGTKLEIK

[0239] SEQ ID NO: 19 Nucleotide sequence of the heavy chain variable region of 6F7H3 CAGGTGCAGCTGGTGCAGAGCGGAGCAGAGGTGGTGAAGCCAGGAGCCTCTGTGAAGGTGAGCTGTAAGGCCTCCGGCTACACCTTCACATCCTATTGGATGAACTGGGTGCGGCAGGCACCAGGACAGGGACTGGAGTGGATCGGCATCATCGACCCTTCCGATTCTGAGACCT CTTACGCCCAGAAGTTTCAGGGCAGGGTGACCCTGACAGTGGACAAGAGCACCTCCACAGCCTATATGGAGCTGAGCTCCCTGCGCAGCGAGGACACAGCCGTGTACTATTGCGCCCGGCTGTACAGATGGTATTTTGACGTGTGGGGAGCAGGAACCACAGTGACCGTGTCTAGC

[0240] SEQ ID NO: 20 Amino acid sequence of the heavy chain variable region of 6F7H3 QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWIGIIDPSDSETSYAQKFQGRVTLTVDKSTSTAYMELSSLRSEDTAVYYCARLYRWYFDVWGAGTTVTVSS

[0241] SEQ ID NO: 21 Nucleotide sequence of the light chain variable region of 6F7L3 AACATCGTGATGACCCAGTCCCCAGCCACACTGTCTCTGAGCCCAGGAGAGAGGTGACCCTGTCCTGTAGAGCCTCTGAGATCGTGGGCACATACCTGTCTTGGTATCAGCAGAAGCCAGGACAGGCACCTAGGCTGCTGATCTACGGAGCCAGCACCA GGGCAACAGGCATCCCCGCACGCTTCTCCGGCTCTGGCAGCGGCACCGACTTTACCCTGACAATCAGCTCCCTGCAGCTGAGGATTTTGCCGTGTACTATTGCGGCCAGTCTTACAATTTCCCATATACCTTTGGCGGCGGCACAAAGCTGGAGATCAAG

[0242] SEQ ID NO: 22 Amino acid sequence of the light chain variable region of 6F7L3 NIVMTQSPATLLSPGERVTLSCRASEIVGTYLSWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTDFTLTISSLQPEDFAVYYCGQSYNFPYTFGGGTKLEIK

[0243] SEQ ID NO: 23: Amino acid sequence of the heavy chain framework region FR-H1 of 6F7 QVQLQQPGAELVRPGASVKLSCKAS

[0244] SEQ ID NO: 24: Amino acid sequence of the heavy chain framework region FR-H2 of 6F7 MNWVKQRPGQGLEWIGM

[0245] SEQ ID NO: 25: Amino acid sequence of the heavy chain framework region FR-H3 of 6F7 HNNQMFKDKATLTVDKSSNTAYMHLSSLTSEDSAVYHC

[0246] SEQ ID NO: 26: Amino acid sequence of the heavy chain framework region FR-H4 of 6F7 WGAGTTVTVSS

[0247] SEQ ID NO: 27: Amino acid sequence of the light chain framework region FR-L1 of 6F7 NIVMTQSPKSMSMSLGERVTLSCKAS

[0248] SEQ ID NO: 28: Amino acid sequence of the light chain framework region FR-L2 of 6F7 VSWFQQKPHQSPKLLIY

[0249] SEQ ID NO: 29: Amino acid sequence of the light chain framework region FR-L3 of 6F7 NRYTGVPDRFTGSGSATDFLTISNVQAEDLADYHC

[0250] SEQ ID NO: 30 Amino acid sequence of the light chain framework region FR-L4 of 6F7 FGGGTKLEIK

[0251] SEQ ID NO: 31: Amino acid sequence of the framework region FR-H1 of 6F7H1 QVQLVQSGAEVVKPGASVKLSCKAS

[0252] SEQ ID NO: 32: Amino acid sequence of the framework region FR-H2 of 6F7H1 MNWVRQRPGQGLEWIGM

[0253] SEQ ID NO: 33: Amino acid sequence of the framework region FR-H3 of 6F7H1 HNAQKFQGKATLTVDKSTSTAYMHLSSLRSEDTAVYYC

[0254] SEQ ID NO: 34: Amino acid sequence of the framework region FR-H4 of 6F7H1 WGAGTTVTVSS

[0255] SEQ ID NO: 35: Amino acid sequence of the framework region FR-L1 of 6F7L1 NIVMTQSPATMSMSPGERVTLSCRAS

[0256] SEQ ID NO: 36: Amino acid sequence of the framework region FR-L2 of 6F7L1 VSWFQQKPGQAPRLLIY

[0257] SEQ ID NO: 37: Amino acid sequence of the framework region FR-L3 of 6F7L1 NRYTGVPARFSGSGSGTDFTLTISSVQPEDLADYHC

[0258] SEQ ID NO: 38: Amino acid sequence of the framework region FR-L4 of 6F7L1 FGGGTKLEIK

[0259] SEQ ID NO: 39: Amino acid sequence of the framework region FR-H1 of 6F7H2 QVQLVQSGAEVVKPGASVKVSCKAS

[0260] SEQ ID NO: 40: Amino acid sequence of the framework region FR-H2 of 6F7H2 MNWVRQRPGQGLEWIGI

[0261] SEQ ID NO: 41: Amino acid sequence of the framework region FR-H3 of 6F7H2 SNAQKFQGRVTLTVDKSTSTAYMHLSSLRSEDTAVYYC

[0262] SEQ ID NO: 42: Amino acid sequence of the framework region FR-H4 of 6F7H2 WGAGTTVTVSS

[0263] SEQ ID NO: 43: Amino acid sequence of the framework region FR-L1 of 6F7L2 NIVMTQSPATLSLSPGERVTLSCRAS

[0264] SEQ ID NO: 44: Amino acid sequence of the framework region FR-L2 of 6F7L2 VSWFQQKPGQAPRLLIY

[0265] SEQ ID NO: 45: Amino acid sequence of the framework region FR-L3 of 6F7L2 NRATGIPARFSGSGSGTDFTLTISSLQPEDLADYYC

[0266] SEQ ID NO: 46: Amino acid sequence of the framework region FR-L4 of 6F7L2 FGGGTKLEIK

[0267] SEQ ID NO: 47: Amino acid sequence of the framework region FR-H1 of 6F7H3 QVQLVQSGAEVVKPGASVKVSCKAS

[0268] SEQ ID NO: 48: Amino acid sequence of the framework region FR-H2 of 6F7H3 MNWVRQAPGQGLEWIGI

[0269] SEQ ID NO: 49: Amino acid sequence of the framework region FR-H3 of 6F7H3 SYAQKFQGRVTLTVDKSTSTAYMELSSLRSEDTAVYYC

[0270] SEQ ID NO: 50 Amino acid sequence of the framework region FR-H4 of 6F7H3 WGAGTTVTVSS

[0271] SEQ ID NO: 51: Amino acid sequence of the framework region FR-L1 of 6F7L3 NIVMTQSPATLSLSPGERVTLSCRAS

[0272] SEQ ID NO: 52: Amino acid sequence of the framework region FR-L2 of 6F7L3 LSWYQQKPGQAPRLLIY

[0273] SEQ ID NO: 53: Amino acid sequence of the framework region FR-L3 of 6F7L3 TRATGIPARFSGSGSGTDFTLTISSLQPEDFAVYYC

[0274] SEQ ID NO: 54: Amino acid sequence of the framework region FR-L4 of 6F7L3 FGGGTKLEIK

[0275] SEQ ID NO: 55 Amino acid sequence of the heavy chain constant region of IgG1M ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0276] SEQ ID NO: 56: Amino acid sequence of heavy chain constant region Ig gamma-4 chain C region ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0277] SEQ ID NO: 57 Amino acid sequence of the light chain constant region Ig kappa chain C region RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0278] SEQ ID NO: 58 Amino acid sequence of heavy chain constant region Ig gamma-1 chain C region ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0279] SEQ ID NO: 59: Amino acid sequence of the heavy chain of 6F7H1L1(G1M) QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMNWVRQRPGQGLEWIGMIDPSDSETHNAQKFQGKATLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPPAPEAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0280] SEQ ID NO: 60: Amino acid sequence of the light chain of 6F7H1L1 (G1M) NIVMTQSPATMSMSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRYTGVPARFSGSGSGTDFTLTISSVQPEDLADYHCGQSYNFPYTFGGGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0281] SEQ ID NO: 61: Amino acid sequence of the heavy chain of 6F7H2L2 (G1M) QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYWMNWVRQRPGQGLEWIGIIDPSDSETSNAQKFQGRVTLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPPAPEAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0282] SEQ ID NO: 62: Amino acid sequence of the light chain of 6F7H2L2 (G1M) NIVMTQSPATLLSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRATGIPARFSGSGSGTDFTLTISSLQPEDLADYYCGQSYNFPYTFGGGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0283] SEQ ID NO: 63: Amino acid sequence of the heavy chain of 6F7H3L3 (G1M) QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWIGIIDPSDSETSYAQKFQGRVTLTVDKSTSTAYMELSSLRSEDTAVYYCARLYRWYFDVWGAGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPPAPEAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0284] SEQ ID NO: 6F764 Amino acid sequence of the light chain of H3L3(G1M) NIVMTQSPATLLSPGERVTLSCRASEIVGTYLSWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTDFTLTISSLQPEDFAVYYCGQSYNFPYTFGGGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0285] SEQ ID NO: 65: Amino acid sequence of the heavy chain of 6F7H1L1 (hG4) QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMNWVRQRPGQGLEWIGMIDPSDSETHNAQKFQGKATLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGT TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0286] SEQ ID NO: 66: Amino acid sequence of the light chain of 6F7H1L1 (hG4) NIVMTQSPATMSMSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRYTGVPARFSGSGSGTDFTLTISSVQPEDLADYHCGQSYNFPYTFGGGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0287] SEQ ID NO: 67: Amino acid sequence of the heavy chain of 6F7H2L2 (hG4) QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYWMNWVRQRPGQGLEWIGIIDPSDSETSNAQKFQGRVTLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGT TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0288] SEQ ID NO: 68: Amino acid sequence of the light chain of 6F7H2L2 (hG4) NIVMTQSPATLLSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRATGIPARFSGSGSGTDFTLTISSLQPEDLADYYCGQSYNFPYTFGGGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0289] SEQ ID NO: 69: Amino acid sequence of the heavy chain of 6F7H3L3 (hG4) QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWIGIIDPSDSETSYAQKFQGRVTLTVDKSTSTAYMELSSLRSEDTAVYYCARLYRWYFDVWGAGT TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0290] SEQ ID NO: 70 Amino acid sequence of the light chain of 6F7H3L3 (hG4) NIVMTQSPATLLSPGERVTLSCRASEIVGTYLSWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTDFTLTISSLQPEDFAVYYCGQSYNFPYTFGGGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0291] SEQ ID NO: 71 mFc tag sequence PRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAP IERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0292] SEQ ID NO: 72 Heavy chain sequence of hIgG EVQLEQSGAELMKPGASVKISCKATGYTFTTYWIEWIKQRPGHSLEWIGEILPGSDSTYYNEKVKGKVTFTADASSNTAYMQLSSLTSEDSAVYYCARGDGFYVYWGQGT TLTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0293] SEQ ID NO: 73 Light chain sequence of hIgG DIELTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYTSQSMSGIPSRFSGSGGTDFTLSINSVETEDFGVYFCQQSGSWPRTFGGGTKLDIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0294] SEQ ID NO: 74 Amino acid sequence of TEV ENLYFQG

[0295] SEQ ID NO: 75 Heavy chain variable region sequence of hIgG EVQLEQSGAELMKPGASVKISCKATGYTFTTYWIEWIKQRPGHSLEWIGEILPGSDSTYYNEKVKGKVTFTADASSNTAYMQLSSLTSEDSAVYYCARGDGFYVYWGQGTTLTVSS

[0296] SEQ ID NO: 76 hIgG light chain variable region sequence DIELTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYTSQSMSGIPSRFSGSGGTDFTLSINSVETEDFGVYFCQQSGSWPRTFGGGTKLDIK

[0297] SEQ ID NO: 77 Nucleic acid sequence of the heavy chain of CP004 (hG1TM)

[0298] SEQ ID NO: 78 Amino acid sequence of the heavy chain of CP004 (hG1TM) (full length) EVQLVESGGGLVQPGGSLRLSCAAS GFAFSSYD MSWVRQAPGKGLDWVAT ISGGGRYT YYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYC ANRYGEAWFAY WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSQVQLVESGAEVKKPGASVKVSCKAS GYSFTGYT MNWVRQAPGQCLEWIGL INPYNNIT NYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFC ARLDYRSY WGQGTLVTVSAGGGGSGGGGSGGGGSGGGGSQAVVTQEPSLTVSPGGTVTLTCGSS TGAVTTSNF PNWVQQKPGQAPRSLIG GTN NKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYC ALWYSNHWV FGCGTKLTVLR (Note: the underlined parts represent the CDR sequences)

[0299] SEQ ID NO: 79 Nucleic acid sequence of the light chain of CP004 (hG1TM) GACATTCAGATGACTCAGAGCCCCTCCTCCATGTCCGCCTCTGTGGGCGACAGGGTCACCTTCACATGCCGCGCTAGTCAGGATATCAACACCTACCTGAGCTGGTTTCAGCAGAAGCCAGGGAAAAGCCCCAAGACACTGATCTACCGGGCTAATAGACTGGTGTCTGGAGTCCCAAGTCGGTTCAGTGGCTCAGGGAGCGGACAGGACTACACTCTGACCATCAGCTCCCTGCAGCCTGAGGACATGGCAACCTACTATTGCCTGCAGTATGATGAGTTCCCACTGACCTTTGGCGCCGGGACAAAACTGGAGCTGAAGCGAACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACGAACAGCTGAAATCAGGCACAGCCAGCGTGGTCTGTCTGCTGAACAATTTCTACCCTAGAGAGGCAAAAGTGCAGTGGAAGGTCGATAACGCCCTGCAGTCCGGCAACAGCCAGGAGAGTGTGACTGAACAGGACTCAAAAGATAGCACCTATTCCCTGTCTAGTACACTGACTCTGTCCAAGGCTGATTACGAGAAGCACAAAGTGTATGCATGCGAAGTGACACATCAGGGACTGTCAAGCCCCGTGACTAAGTCTTTTAACCGGGGCGAATGT

[0300] Amino acid sequence (full length) of the light chain of SEQ ID NO: 80 CP004 (hG1TM) DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0301] SEQ ID NO: 81 Nucleic acid sequence of the heavy chain of Penpulimab: (1344 bp)

[0302] SEQ ID NO: 82 Amino acid sequence of the heavy chain of Penpulimab: (448 aa) EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0303] SEQ ID NO: 83 Nucleic acid sequence of the light chain of Penpulimab: (642 bp) GACATTCAGATGACTCAGAGCCCCTCCTCCATGTCCGCCTCTGTGGGCGACAGGGTCACCTTCACATGCCGCGCTAGTCAGGATATCAACACCTACCTGAGCTGGTTTCAGCAGAAGCCAGGGAAAAGCCCCAAGACACTGATCTACCGGGCTAATAGAC TGGTGTCTGGAGTCCCAAGTCGGTTCAGTGGCTCAGGGAGCGGACAGGACTACACTCTGACCATCAGCTCCCTGCAGCCTGAGGACATGGCAACCTACTATTGCCTGCAGTATGATGAGTTCCCACTGACCTTTGGCGCCGGGACAAAACTGGAGCTGAAG CGAACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACGAACAGCTGAAATCAGGCACAGCCAGCGTGGTCTGTCTGCTGAACAATTTCTACCCTAGAGAGGCAAAAGTGCAGTGGAAGGTCGATAACGCCCTGCAGTCCGGCAACAGCCAGG AGAGTGTGACTGAACAGGACTCAAAGATAGCACCTATTCCCTGTCTAGTACACTGACTCTGTCCAAGGCTGATTACGAGAAGCACAAAGTGTATGCATGCGAAGTGACACATCAGGGACTGTCAAGCCCCGTGACTAAGTCTTTTAACCGGGGCGAATGT

[0304] SEQ ID NO: 84 Amino acid sequence of the light chain of Penpulimab: (214 aa) DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0305] SEQ ID NO: 121 Amino acid sequence of the heavy chain variable region of Penpulimab EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS

[0306] SEQ ID NO: 122 Amino acid sequence of the light chain variable region of Penpulimab DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK

[0307] SEQ ID NO: 123 HCDR1 of Penpulimab GFAFSSYD

[0308] SEQ ID NO: 124 HCDR2 of Penpulimab ISGGGRYT

[0309] SEQ ID NO: 125 HCDR3 of Penpulimab ANRYGEAWFAY

[0310] SEQ ID NO: 126 LCDR1 of Penpulimab QDINTY

[0311] SEQ ID NO: 127 LCDR2 of Penpulimab RAN

[0312] SEQ ID NO: 128 LCDR3 of Penpulimab LQYDEFPLT

[0313] SEQ ID NO: 85 Amino acid sequence of the heavy chain of Hu5F9-G4 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYNMHWVRQAPGQRLEWMGTIYPGNDDTSYNQKFKDRVTITADTSASTAYMELSSLRSEDTAVYYCARGGYRAMDYWGQGT LVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0314] SEQ ID NO: 86 Amino acid sequence of the light chain of Hu5F9-G4 DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKL EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0315] SEQ ID NO: 87: Amino acid sequence of the heavy chain variable region of 14C12 EVKLVESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQTPEKRLEWVATISGGGRYTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTALYYCANRYGEAWFAYWGQGTLVTVSA

[0316] SEQ ID NO: 88: Amino acid sequence of the light chain variable region of 14C12 DIKMTQSPSSMYASLGERVTFTCKASQDINTYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPLTFGAGTKLELK

[0317] SEQ ID NO: 89 HCDR1 of 14C12 GFAFSSYD

[0318] SEQ ID NO:90 HCDR2 of 14C12 ISGGGRYT

[0319] SEQ ID NO:91 HCDR3 of 14C12 ANRYGEAWFAY

[0320] SEQ ID NO: 92 LCDR1 of 14C12 QDINTY

[0321] SEQ ID NO: 93 LCDR2 of 14C12 RAN

[0322] SEQ ID NO: 94 LCDR3 of 14C12 LQYDEFPLT

[0323] SEQ ID NO: 95 Amino acid sequence of the heavy chain variable region of 4G10 QVKLQESGPELVKPGASMKISKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNNITNYNQKFMGKATFTVDKSSSTAYMELLRLTSEDSGVYFCARLDYRSYWGQGTLVTVSAAKTTPPSVY

[0324] SEQ ID NO: 96 Amino acid sequence of the light chain variable region of 4G10 QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNFANWVQEKPDHLFTSLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVLGQPKSSPSVTLFQGQFC

[0325] SEQ ID NO: 97 HCDR1 of 4G10 GYSFTGYT

[0326] SEQ ID NO:98 HCDR2 of 4G10 INPYNNIT

[0327] SEQ ID NO: 99 HCDR3 of 4G10 ARLDYRSY

[0328] SEQ ID NO: 100 LCDR1 of 4G10 TGAVTTSNF

[0329] SEQ ID NO: 101 LCDR2 of 4G10 GTN

[0330] SEQ ID NO: 102 LCDR3 of 4G10 ALWYSNHWV

[0331] SEQ ID NO: 103 Amino acid sequence of the heavy chain variable region of humanized monoclonal antibody 14C12H1L1: (118 aa) EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS

[0332] SEQ ID NO: 104 Amino acid sequence of the light chain variable region of 14C12H1L1(M): (108 aa, positions of mutations in the amino acid sequence based on 14C12H1L1 are underlined) DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK R

[0333] SEQ ID NO: 105 Amino acid sequence of HCDR1 of the heavy chain variable region of 14C12H1L1(M) GFAFSSYD

[0334] SEQ ID NO: 106: Amino acid sequence of HCDR2 of the heavy chain variable region of 14C12H1L1(M) ISGGGRYT

[0335] SEQ ID NO: 107: Amino acid sequence of HCDR3 of the heavy chain variable region of 14C12H1L1(M) ANRYGEAWFAY

[0336] SEQ ID NO: 108 Amino acid sequence of LCDR1 of the light chain variable region of 14C12H1L1(M) QDINTY

[0337] SEQ ID NO: 109: Amino acid sequence of LCDR2 of the light chain variable region of 14C12H1L1(M) RAN

[0338] SEQ ID NO: 110 Amino acid sequence of LCDR3 of the light chain variable region of 14C12H1L1(M) LQYDEFPLT

[0339] SEQ ID NO: 111 Amino acid sequence of the heavy chain variable region of Bevacizumab (Bevacizumab-Hv): (123 aa) EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS

[0340] SEQ ID NO: 112 Amino acid sequence of the light chain variable region of Bevacizumab (Bevacizumab-Lv): (107 aa) DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK

[0341] SEQ ID NO:113 Bevacizumab Amino acid sequence of HCDR1 in the heavy chain variable region of GYTFTNYG

[0342] SEQ ID NO:114 Bevacizumab Amino acid sequence of HCDR2 in the heavy chain variable region of INTYTGEP

[0343] SEQ ID NO:115 Bevacizumab Amino acid sequence of HCDR3 in the heavy chain variable region of AKYPHYYGSSHWYFDV

[0344] SEQ ID NO:116 Bevacizumab Amino acid sequence of LCDR1 in the light chain variable region of QDISNY (SEQ ID NO: 116)

[0345] SEQ ID NO:117 Bevacizumab Amino acid sequence of LCDR2 in the light chain variable region of FTS

[0346] SEQ ID NO:118 Bevacizumab Amino acid sequence of LCDR3 in the light chain variable region of QQYSTVPWT

[0347] SEQ ID NO: 119 Amino acid sequence of linker 1 GGGGSGGGGSGGGGS

[0348] SEQ ID NO: 120 Amino acid sequence of linker 2 GGGGSGGGGSGGGGSGGGGS

[0349] SEQ ID NO: 129: Amino acid sequence of the heavy chain variable region of 14C12H1L1 EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS

[0350] SEQ ID NO: 130 Amino acid sequence of the light chain variable region of 14C12H1L1 DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK

[0351] SEQ ID NO: 131: Amino acid sequence of the heavy chain variable region of 4G10H1L1 QVQLVESGAELVKPGASMKISCKASGYSFTGYTMNWVKQAPGQGLEWIGLINPYNNITNYNQKFMGKATFTVDKSISTAYMELSRLTSDDSGVYFCARLDYRSYWGQGTLVTVSA

[0352] SEQ ID NO: 132 Amino acid sequence of the light chain variable region of 4G10H1L1 QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFANWVQEKPGQAFRSLIGGTNNRASWVPARFSGSLLGGKAALTISGAQPEDEAEYFCALWYSNHWVFGGGTKLTVL

[0353] SEQ ID NO: 133: Amino acid sequence of the heavy chain variable region of 4G10H3L3 QVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA

[0354] SEQ ID NO: 134: Amino acid sequence of the light chain variable region of 4G10H3L3 QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGGGTKLTVL

[0355] SEQ ID NO: 135 Amino acid sequence of 4G10H1V(M) QVQLVESGAELVKPGASMKISCKASGYSFTGYTMNWVKQAPGQCLEWIGLINPYNNITNYNQKFMGKATFTVDKSISTAYMELSRLTSDDSGVYFCARLDYRSYWGQGTLVTVSA

[0356] SEQ ID NO: 136: Amino acid sequence of 4G10L1V(M) QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFANWVQEKPGQAFRSLIGGTNNRASWVPARFSGSLLGGKAALTISGAQPEDEAEYFCALWYSNHWVFGCGTKLTVLR

[0357] SEQ ID NO: 137: Amino acid sequence of 4G10H3V(M) QVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA

[0358] SEQ ID NO: 138: Amino acid sequence of 4G10L3V(M) QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGCGTKLTVLR

[0359] SEQ ID NO: 139 Amino acid sequence of the heavy chain of the immunoglobulin portion in CP004 (hG1TM) EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0360] SEQ ID NO: 140 Amino acid sequence of the heavy chain of Bevacizumab EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVW GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0361] SEQ ID NO: 141: Amino acid sequence of the heavy chain of VP101 (hG1DM) (SEQ ID NO:141)

[0362] SEQ ID NO: 142 Nucleic acid sequence of the heavy chain of VP101 (hG1DM)

[0363] SEQ ID NO: 143: Amino acid sequence of the light chain of VP101 (hG1DM) DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 143)

[0364] SEQ ID NO: 144 Nucleotide sequence of the light chain of VP101 (hG1DM) GATATTCAGATGACTCAGAGCCCCTCCTCCCTGTCCGCCTCTGTGGGCGACAGGGTCACCATCACATGCAGTGCTTCACAGGATATTTCCAACTACCTGAATTGGTATCAGCAGAAGCCAGGAAAAGCACCCAAGGTGCTGATCTACTTCACTAGCTCCCTGCACTCAGGAGTGCCAAGCCGGTTCAGCGGATCCGGATCTGGAACCGACTTTACTCTGACCATTTCTAGTCTGCAGCCTGAGGATTTCGCTACATACTATTGCCAGCAGTATTCTACCGTGCCATGGACATTTGGCCAGGGGACTAAAGTCGAGATCAAGCGGACCGTGGCCGCTCCCAGTGTCTTCATTTTTCCCCCTAGCGACGAACAGCTGAAATCCGGGACAGCCTCTGTGGTCTGTCTGCTGAACAACTTCTACCCTAGAGAGGCAAAAGTGCAGTGGAAGGTCGATAACGCCCTGCAGAGTGGCAATTCACAGGAGAGCGTGACAGAACAGGACTCCAAAGATTCTACTTATAGTCTGTCAAGCACACTGACTCTGAGCAAGGCTGACTACGAAAAGCATAAAGTGTATGCATGTGAGGTCACCCACCAGGGGCTGAGCAGTCCAGTCACCAAGTCATTCAACAGAGGCGAGTGC (SEQ ID NO: 144)

[0365] SEQ ID NO: 145 Nucleotide sequence of the heavy chain variable region of Bevacizumab: (369 bp) GAGGTGCAGCTGGTCGAGTCCGGGGGGGGGCTGGTGCAGCCAGGCGGGTCTCTGAGGCTGAGTTGCGCCGCTTCAGGGTACACCTTCACAAACTATGGAATGAATTGGGTGCGCCAGGCACCAGGAAAGGGACTGGAGTGGGTCGGCTGGATCAACACTTACACCGGGGAACCTACCTATGCAGCCGACTTTAAGCGGCGGTTCACCTTCAGCCTGGATACAAGCAAATCCACTGCCTACCTGCAGATGAACAGCCTGCGAGCTGAGGACACCGCAGTCTACTATTGTGCTAAATATCCCCACTACTATGGGAGCAGCCATTGGTATTTTGACGTGTGGGGGCAGGGGACTCTGGTGACAGTGAGCAGC(SEQ ID NO: 145)

[0366] SEQ ID NO: 146 Nucleotide sequence of the light chain variable region of Bevacizumab: (321 bp) GATATTCAGATGACTCAGAGCCCCTCCTCCCTGTCCGCCTCTGTGGGCGACAGGGTCACCATCACATGCAGTGCTTCACAGGATATTTCCAACTACCTGAATTGGTATCAGCAGAAGCCAGGAAAAGCACCCAAGGTGCTGATCTACTTCACTAGCTCCCTGCACTCAGGAGTGCCAAGCCGGTTCAGCGGATCCGGATCTGGAACCGACTTTACTCTGACCATTTCTAGTCTGCAGCCTGAGGATTTCGCTACATACTATTGCCAGCAGTATTCTACCGTGCCATGGACATTTGGCCAGGGGACTAAAGTCGAGATCAAG(SEQ ID NO: 146)

Claims

1. A pharmaceutical composition, preferably for use in the treatment of a tumor, comprising component A and component B, wherein component A is an antibody or an antigen-binding fragment thereof that specifically binds to CD47; wherein, component B is one or more selected from component B1, component B2, and component B3, wherein component B1 is a bispecific antibody or an antigen-binding fragment thereof, component B2 is a tumor chemotherapeutic drug, and component B3 is an anti-PD-1 monoclonal antibody or an antigen-binding fragment thereof; Preferably, the composition further comprises a component C, which is a tumor therapeutic agent, and which is different from component B; For example, according to the Kabat, IMGT, Chothia or AbM numbering systems: The antibody that specifically binds to CD47 comprises the following CDR sequences contained in the heavy chain variable region and the light chain variable region: (1) HCDR1, HCDR2, and HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 2; LCDR1, LCDR2, LCDR3 contained in the light chain variable region shown in SEQ ID NO: 4, or (2) HCDR1, HCDR2, and HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 12; LCDR1, LCDR2, LCDR3 contained in the light chain variable region shown in SEQ ID NO: 14, or (3) HCDR1, HCDR2, and HCDR3 contained in the heavy chain variable region represented by SEQ ID NO: 16; LCDR1, LCDR2, LCDR3 contained in the light chain variable region shown in SEQ ID NO: 18, or (4) HCDR1, HCDR2, and HCDR3 contained in the heavy chain variable region represented by SEQ ID NO: 20; LCDR1, LCDR2, and LCDR3 contained in the light chain variable region shown in SEQ ID NO: 22 (Preferably, according to the IMGT numbering system, the antibody is HCDR1 comprising or consisting of the sequence shown in SEQ ID NO:5 or a variant thereof, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO:6 or a variant thereof, and The antibody comprises an HCDR3 comprising or composed of the sequence shown in SEQ ID NO: 7 or a variant thereof, LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:8 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:9 or a variant thereof; and and further comprising an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 10 or a variant thereof. Wherein, the bispecific antibody is an anti-PD-1-anti-CTLA4 antibody or an anti-PD-1-anti-VEGFA antibody or a combination of both, the bispecific antibody comprises a first protein functional domain and a second protein functional domain, in which the first protein functional domain targets PD-1 and the second protein functional domain targets CTLA4 or VEGFA, in which the first protein functional domain is an immunoglobulin and the second protein functional domain is a single chain antibody, or the first protein functional domain is a single chain antibody and the second protein functional domain is an immunoglobulin; Preferably, two single chain antibody molecules are connected to one immunoglobulin molecule (preferably, the two single chain antibody molecules are the same), preferably, the immunoglobulin is an IgG1 isoform (preferably, a human IgG1 isoform), preferably, the single chain antibody is connected to the N-terminus or C-terminus of the heavy chain of the immunoglobulin, wherein the first protein functional domain and the second protein functional domain are independently one, two or more than two, preferably, the first protein functional domain is directly connected to the second protein functional domain or is connected via a first connecting fragment. and / or the heavy chain variable region of the single chain antibody is connected directly or via a second connecting fragment to the light chain variable region of the single chain antibody, the first connecting fragment and the second connecting fragment being homologous or different, preferably the connecting fragment is (GGGGS)n, n being a positive integer, more preferably n being 1, 2, 3, 4, 5 or 6, preferably the amino acid sequences of the first connecting fragment and the second connecting fragment are independently selected from SEQ ID NO: 119 and SEQ ID NO: 120, more preferably the first connecting fragment and the second connecting fragment both comprise the amino acid sequence shown in SEQ ID NO: 120, Among them, when the bispecific antibody is an anti-PD-1-anti-CTLA4 antibody, The first protein functional region comprises HCDR1 to HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 87 and LCDR1 to LCDR3 contained in the light chain variable region shown in SEQ ID NO: 88 (preferably, according to the IMGT numbering system, the first protein functional region comprises or is composed of HCDR1, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 90 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 91 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 92 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 93 or a variant thereof; and and an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 94 or a variant thereof; The second protein functional region comprises HCDR1 to HCDR3 in the heavy chain variable region as set forth in SEQ ID NO: 95 and LCDR1 to LCDR3 in the light chain variable region as set forth in SEQ ID NO: 96 (preferably, according to the IMGT numbering system, the second protein functional region comprises or is constituted by the sequence set forth in SEQ ID NO: 97 or a variant thereof, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 98 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 99 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 100 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 101 or a variant thereof; and and an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 102 or a variant thereof; or Among these, when the bispecific antibody is an anti-PD-1-anti-VEGFA antibody, The first protein functional region comprises HCDR1 to HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 103 and LCDR1 to LCDR3 contained in the light chain variable region shown in SEQ ID NO: 104 (preferably, according to the IMGT numbering system, the first protein functional region comprises or is composed of HCDR1, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 106 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 107 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 108 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 109 or a variant thereof; and and an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 110 or a variant thereof; The second protein functional region comprises HCDR1 to HCDR3 in the heavy chain variable region as set forth in SEQ ID NO: 111 and LCDR1 to LCDR3 in the light chain variable region as set forth in SEQ ID NO: 112 (preferably, according to the IMGT numbering system, the second protein functional region comprises or is constituted by the sequence set forth in SEQ ID NO: 113 or a variant thereof, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 114 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 115 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 116 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 117 or a variant thereof; and comprising an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 118 or a variant thereof; Among them, The anti-PD1 monoclonal antibody comprises HCDR1 to HCDR3 contained in a heavy chain variable region as set forth in SEQ ID NO: 121 and LCDR1 to LCDR3 contained in a light chain variable region as set forth in SEQ ID NO: 122 (preferably, according to the IMGT numbering system, the anti-PD1 monoclonal antibody comprises or is composed of HCDR1, HCDR2, HCDR3, ...1, HCDR2, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR1, HCDR2 comprising or consisting of the sequence shown in SEQ ID NO: 124 or a variant thereof; HCDR3 comprising or consisting of the sequence shown in SEQ ID NO: 125 or a variant thereof; LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 126 or a variant thereof; LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 127 or a variant thereof; and and an LCDR3 comprising or consisting of the sequence set forth in SEQ ID NO: 128 or a variant thereof; wherein the variant sequence has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology to the corresponding sequence, or the variant sequence has one or more (preferably one, two or three) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence, Pharmaceutical compositions.

2. The antibody that specifically binds to CD47 further comprises a framework region FR of a heavy chain variable region and a framework region FR of a light chain variable region selected from the group consisting of: (1) The framework region FR of the heavy chain variable region includes FR-H1, FR-H2, FR-H3, and FR-H4, among which FR-H1 includes or is composed of the amino acid sequence of SEQ ID NO: 23 or a variant thereof, FR-H2 includes or is composed of the amino acid sequence of SEQ ID NO: 24 or a variant thereof, FR-H3 includes or is composed of the amino acid sequence of SEQ ID NO: 25 or a variant thereof, and FR-H4 includes or is composed of the amino acid sequence of SEQ ID NO: 26 or a variant thereof; The framework region FR of the light chain variable region comprises FR-L1, FR-L2, FR-L3 and FR-L4, among which FR-L1 comprises or is composed of the amino acid sequence of SEQ ID NO: 27 or a variant thereof, FR-L2 comprises or is composed of the amino acid sequence of SEQ ID NO: 28 or a variant thereof, FR-L3 comprises or is composed of the amino acid sequence of SEQ ID NO: 29 or a variant thereof, and FR-L4 comprises or is composed of the amino acid sequence of SEQ ID NO: 30 or a variant thereof; (2) The framework region FR of the heavy chain variable region includes FR-H1, FR-H2, FR-H3, and FR-H4, among which FR-H1 includes or is composed of the amino acid sequence of SEQ ID NO: 31 or a variant thereof, FR-H2 includes or is composed of the amino acid sequence of SEQ ID NO: 32 or a variant thereof, FR-H3 includes or is composed of the amino acid sequence of SEQ ID NO: 33 or a variant thereof, and FR-H4 includes or is composed of the amino acid sequence of SEQ ID NO: 34 or a variant thereof; The framework region FR of the light chain variable region comprises FR-L1, FR-L2, FR-L3 and FR-L4, among which FR-L1 comprises or is composed of the amino acid sequence of SEQ ID NO: 35 or a variant thereof, FR-L2 comprises or is composed of the amino acid sequence of SEQ ID NO: 36 or a variant thereof, FR-L3 comprises or is composed of the amino acid sequence of SEQ ID NO: 37 or a variant thereof, and FR-L4 comprises or is composed of the amino acid sequence of SEQ ID NO: 38 or a variant thereof; (3) The framework region FR of the heavy chain variable region includes FR-H1, FR-H2, FR-H3, and FR-H4, among which FR-H1 includes or is composed of the amino acid sequence of SEQ ID NO: 39 or a variant thereof, FR-H2 includes or is composed of the amino acid sequence of SEQ ID NO: 40 or a variant thereof, FR-H3 includes or is composed of the amino acid sequence of SEQ ID NO: 41 or a variant thereof, and FR-H4 includes or is composed of the amino acid sequence of SEQ ID NO: 42 or a variant thereof; The framework region FR of the light chain variable region comprises FR-L1, FR-L2, FR-L3 and FR-L4, among which FR-L1 comprises or consists of the amino acid sequence of SEQ ID NO: 43 or a variant thereof, FR-L2 comprises or consists of the amino acid sequence of SEQ ID NO: 44 or a variant thereof, FR-L3 comprises or consists of the amino acid sequence of SEQ ID NO: 45 or a variant thereof, and FR-L4 comprises or consists of the amino acid sequence of SEQ ID NO: 46 or a variant thereof; (4) The framework region FR of the heavy chain variable region includes FR-H1, FR-H2, FR-H3, and FR-H4, among which FR-H1 includes or is composed of the amino acid sequence of SEQ ID NO: 47 or a variant thereof, FR-H2 includes or is composed of the amino acid sequence of SEQ ID NO: 48 or a variant thereof, FR-H3 includes or is composed of the amino acid sequence of SEQ ID NO: 49 or a variant thereof, and FR-H4 includes or is composed of the amino acid sequence of SEQ ID NO: 50 or a variant thereof; The framework region FR of the light chain variable region comprises FR-L1, FR-L2, FR-L3 and FR-L4, among which FR-L1 comprises or is composed of the amino acid sequence of SEQ ID NO: 51 or a variant thereof, FR-L2 comprises or is composed of the amino acid sequence of SEQ ID NO: 52 or a variant thereof, FR-L3 comprises or is composed of the amino acid sequence of SEQ ID NO: 53 or a variant thereof, and FR-L4 comprises or is composed of the amino acid sequence of SEQ ID NO: 54 or a variant thereof; wherein the variant sequence has at least 80%, preferably at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or 99% homology to the corresponding sequence or has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence, 2. The pharmaceutical composition of claim 1.

3. The antibody that specifically binds to CD47 is （1） A heavy chain variable region comprising or consisting of the amino acid sequence shown in SEQ ID NO:2 or a variant thereof; A light chain variable region comprising or consisting of the amino acid sequence set forth in SEQ ID NO:4 or a variant thereof; （2） A heavy chain variable region comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 12 or a variant thereof; A light chain variable region comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 14 or a variant thereof; （3） A heavy chain variable region comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 16 or a variant thereof; A light chain variable region comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 18 or a variant thereof; （4） A heavy chain variable region comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 20 or a variant thereof; A light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 22 or a variant thereof, or comprising said sequence; The first protein functional domain of the anti-PD-1-anti-CTLA4 antibody is （1） A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 87 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 88 or a variant thereof; （2） A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 129 or a variant thereof; A light chain variable region comprising the sequence shown in SEQ ID NO: 130 or a variant thereof, or consisting of said sequence, The second protein functional domain of the anti-PD-1-anti-CTLA4 antibody is （1） A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 95 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 96 or a variant thereof; （2） A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 133 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 134 or a variant thereof; （3） A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 135 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 136 or a variant thereof; （4） A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 137 or a variant thereof; A light chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 138 or a variant thereof; （5） A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 131 or a variant thereof; A light chain variable region comprising the sequence shown in SEQ ID NO: 132 or a variant thereof, or consisting of said sequence, Preferably, the heavy chain amino acid sequence contained in the immunoglobulin of the anti-PD-1-anti-CTLA4 antibody is as shown in SEQ ID NO: 139, and targets PD-1; The first protein functional domain of the anti-PD-1-anti-VEGFA antibody is （1） A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 103 or a variant thereof; A light chain variable region comprising the sequence shown in SEQ ID NO: 104 or a variant thereof, or consisting of said sequence, The second protein functional domain of the anti-PD-1-anti-VEGFA antibody is （1） A heavy chain variable region comprising or consisting of the sequence set forth in SEQ ID NO: 111 (preferably encoded by the nucleotide sequence set forth in SEQ ID NO: 145) or a variant thereof; A light chain variable region comprising the sequence shown in SEQ ID NO: 112 (preferably encoded by the nucleotide sequence shown in SEQ ID NO: 146) or a variant thereof, or composed of said sequence; Preferably, the heavy chain amino acid sequence contained in the immunoglobulin of the anti-PD-1-anti-VEGFA antibody is as set forth in SEQ ID NO: 140, and targets VEGFA; The anti-PD-1 monoclonal antibody comprises or is composed of a heavy chain variable region set forth in SEQ ID NO: 121 and a light chain variable region set forth in SEQ ID NO: 122; wherein the variant is an amino acid sequence having at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to the corresponding sequence or having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the corresponding sequence, 2. The pharmaceutical composition of claim 1.

4. The antibody that specifically binds to CD47 further comprises a heavy chain constant region and a light chain constant region, and the constant region is derived from a non-murine species, e.g., a human antibody, preferably derived from human IgG or IgM, more preferably derived from IgG1; preferably, the heavy chain constant region is an Ig gamma-1 chain C region, ACCESSION: P01857 (SEQ ID NO: 58), or an Ig gamma-4 chain C region, ACCESSION: P01861.1 (SEQ ID NO: 56); the light chain constant region is an Ig kappa chain C region, ACCESSION: P01834 (SEQ ID NO: 57); and preferably, the antibody that specifically binds to CD47 is secreted by hybridoma cell line LT012, having deposit number CCTCC NO: 2018135.

2. The pharmaceutical composition of claim 1.

5. the antibody that specifically binds to CD47 and the heavy chain constant region of the immunoglobulin have mutations at any one, two or three positions, including positions 234, 235 and 237, according to the EU numbering system, and after the mutations, the affinity constant of the bispecific antibody for FcγRIIIa and / or C1q is reduced compared to before the mutations, preferably the affinity constant is measured using a Fortebio Octet molecular interaction device; Preferably, said antibody that specifically binds to CD47 comprises the mutations L234A and / or L235A, according to the EU numbering system, More preferably, the heavy chain constant region of the immunoglobulin comprises L234A and L235A, or L234A and G237A, or L235A and G237A, or having one of the combinations of mutations L234A, L235A, and G237A; More preferably, According to the EU numbering system, the heavy chain constant region of said immunoglobulin is and further comprising one of the following combinations of mutations: N297A, D265A, D270A, P238D, L328E, E233D, H268D, P271G, A330R, C226S, C229S, E233P, P331S, S267E, L328F, A330L, M252Y, S254T, T256E, N297Q, P238S, P238A, A327Q, A327G, P329A, K322A, T394D, G236R, G236A, L328R, A330S, P331S, H268A, E318A and K320A.

2. The pharmaceutical composition of claim 1.

6. The antibody that specifically binds to CD47 is (1) a heavy chain represented by SEQ ID NO: 59 and a light chain represented by SEQ ID NO: 60; (2) a heavy chain represented by SEQ ID NO: 61 and a light chain represented by SEQ ID NO: 62; (3) a heavy chain represented by SEQ ID NO: 63 and a light chain represented by SEQ ID NO: 64; (4) A heavy chain represented by SEQ ID NO: 65 and a light chain represented by SEQ ID NO: 66; (5) A heavy chain represented by SEQ ID NO: 67 and a light chain represented by SEQ ID NO: 68, and (6) A heavy chain represented by SEQ ID NO: 69 and a light chain represented by SEQ ID NO: 70 are included in the group consisting of the heavy chain and the light chain, or are composed of them; The anti-PD-1-anti-CTLA4 antibody A heavy chain represented by SEQ ID NO: 78 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 77) and a light chain represented by SEQ ID NO: 80 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 79), The anti-PD-1-anti-VEGFA antibody The heavy chain represented by SEQ ID NO: 141 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 142) and the light chain represented by SEQ ID NO: 143 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 144) are selected from the group consisting of heavy chain and light chain, The anti-PD-1 monoclonal antibody comprises or is composed of a heavy chain and a light chain selected from the group consisting of a heavy chain represented by SEQ ID NO: 82 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 81) and a light chain represented by SEQ ID NO: 84 (preferably encoded by the nucleotide sequence represented by SEQ ID NO: 83); 2. The pharmaceutical composition of claim 1.

7. The antigen-binding fragments include Fab, Fab', F(ab') 2 , Fd, Fv, dAb, Fab / c, complementarity determining region (CDR) fragment, single chain antibody (e.g., scFv), bivalent antibody or domain antibody, 2. The pharmaceutical composition of claim 1.

8. The antibody that specifically binds to CD47 is a humanized antibody, a chimeric antibody, or a multispecific antibody (e.g., a bispecific antibody).

2. The pharmaceutical composition of claim 1.

9. The antibody that specifically binds to CD47 is about 10 -5 Less than m, e.g., about 10 -6 Less than M, about 10 -7 Less than M, about 10 -8 Less than M, about 10 -9 Less than M or about 10 -10 An antibody that binds to human CD47 protein with a KD of less than M or less, or that specifically binds to CD47, binds to human CD47 protein with an EC50 of less than about 100 nM, e.g., less than about 10 nM, less than about 1 nM, less than about 0.9 nM, less than about 0.8 nM, less than about 0.7 nM, less than about 0.6 nM, less than about 0.5 nM, less than about 0.4 nM, less than about 0.3 nM, less than about 0.2 nM, less than about 0.1 nM or less.

2. The pharmaceutical composition of claim 1.

10. The antibody that specifically binds to CD47 is in the form of an antibody conjugate comprising the antibody or antigen-binding fragment thereof that specifically binds to CD47 according to claim 1 and a conjugation moiety that is conjugated to the antibody or antigen-binding fragment thereof that specifically binds to CD47, the conjugation moiety being a purification tag (e.g. His tag), a cytotoxic agent, or a detectable label, preferably a radioisotope, a luminescent substance, a colored substance, an enzyme, or polyethylene glycol, or The antibody that specifically binds to CD47 is in the form of a multispecific antibody, preferably in the form of a bispecific antibody comprising an antibody or antigen-binding fragment thereof that specifically binds to CD47 according to claim 1 and an antibody or antigen-binding fragment thereof against another antigen and / or another antigen epitope, or the antibody that specifically binds to CD47 is in the form of a fusion protein comprising an antibody or antigen-binding fragment thereof that specifically binds to CD47 according to claim 1.

2. The pharmaceutical composition of claim 1.

11. The tumor therapeutic agent is one or more selected from tyrosine kinase inhibitors, DNA polymerase inhibitors, anti-human CD20 antibodies, anti-human PDL-1 antibodies, anti-human PD-1 antibodies, anti-human CTLA-4 antibodies, BCL-2 inhibitors, anti-human EGFR antibodies, anti-human HER2 antibodies, anti-human HER3 antibodies, acalabrutinib, cyclin-dependent kinase inhibitors, anti-human VEGFR2 antibodies, anti-human VEGF antibodies, proteasome inhibitors, angiogenesis inhibitors, Rapidly accelerated fibrosarcoma (RAF) inhibitors, bispecific antibodies, and fusion protein drugs; preferably, the therapeutic agent is Cetuximab, Obinutuzumab, or Rituximab; Preferably, the tumor chemotherapeutic drug is one or more selected from alkylating agents, anthracyclines, antimetabolites, antibiotics, plant-derived and / or hormonal drugs, platinum-based drugs (e.g., cisplatin, carboplatin, oxaliplatin), adriamycins, cyclophosphamide, paclitaxel (e.g., albumin-bound paclitaxel, liposomal paclitaxel, docetaxel), etoposide, gemcitabine, pemetrexed, capecitabine, olaparib, rucaparib, niraparib, talazoparib, fuzuloparib, vinblastines, tamoxifen, megestrol, goserelin, asparaginase, fluorouracil antineoplastic drugs (e.g., 5-fluorouracil), and azacitidine, cytarabine, cyclocytidine; 2. The pharmaceutical composition of claim 1.

12. The pharmaceutical composition further comprises a pharma- ceutically acceptable vector and / or excipient.

2. The pharmaceutical composition of claim 1.

13. When calculated based on the mass of the antibody, the mass ratio of the component A to the component B1 is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, or 5:1; The mass ratio of the component A to the component B3 is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1; or The mass ratio of the component B2 to the component A is 1:(1 to 1000), preferably 1:(5 to 500), and more preferably 1:(10 to 100); Preferably, component A and component B in the pharmaceutical composition are in a form suitable for administration by intravenous drip, subcutaneous, intradermal, intravenous, intramuscular or intralesional injection; 2. The pharmaceutical composition of claim 1.

14. A kit, preferably for use in treating a tumor, comprising product A and product B, wherein said product A comprises an antibody or an antigen-binding fragment thereof that specifically binds to CD47 as defined in claim 1; Product B is one or more selected from product B1, product B2 and product B3, in which product B1 is the bispecific antibody or antigen-binding fragment thereof defined in claim 1 (preferably, when the bispecific antibody is a combination of anti-PD-1-anti-CTLA4 antibody and anti-PD-1-anti-VEGFA antibody, the anti-PD-1-anti-CTLA4 antibody and the anti-PD-1-anti-VEGFA antibody are present in independent packages or in the same package), product B2 is the tumor chemotherapeutic drug defined in claim 1, and product B3 is the anti-PD-1 monoclonal antibody or antigen-binding fragment thereof defined in claim 1, in which product B1, product B2 and product B3 are present in independent packages or in the same package; Preferably, the kit further comprises a product C, which is a tumor therapeutic agent as defined in claim 1, and which is different from product B, Preferably, the kit further comprises a product description. kit.

15. When calculated based on the mass of the antibody, the mass ratio of the product A to the product B1 is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1; The mass ratio of the product A to the product B3 is (1:5) to (5:1), for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1; or the unit dose of the oncology chemotherapy drug is 0.1 mg to 100 mg, 0.5 mg to 50 mg, 1 mg to 20 mg, 2 mg to 15 mg, 4 mg to 12 mg, or 8 mg to 12 mg; Preferably, Product A, Product B or Product C in the kit is in a form suitable for administration by intravenous infusion, subcutaneous injection, intradermal injection, intravenous injection, intramuscular injection or intralesional injection; The kit of claim 14.

16. A method for treating or preventing a tumor, comprising administering to a subject in need thereof an effective amount of component A and component B as defined in claim 1, and preferably further comprising administering to a subject in need thereof an effective amount of component C as defined in claim 1, Preferably, said components A, B and C are administered simultaneously or sequentially, more preferably, said components A, B and C are administered before or after surgical treatment and / or before or after radiation therapy; Preferably, when component B is component B1 and / or component B3, the single dose of component A or component B is 0.1 mg to 100 mg, preferably 1 mg to 10 mg, per kilogram of subject body weight, or the single dose of component A or component B is 10 mg to 1000 mg, preferably 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg or 200 mg, for each subject; Preferably, the unit dose of component B2 is between 0.1 mg and 100 mg, between 0.5 mg and 50 mg, between 1 mg and 20 mg, between 2 mg and 15 mg, between 4 mg and 12 mg or between 8 mg and 12 mg; Preferably, it is administered twice a day to about once every 2 days, or once every 3 days, once every 4 days, once every 5 days, once every 6 days, once every 10 days, once a week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, or once every 6 weeks; Preferably, the administration method is intravenous drip, subcutaneous injection, intradermal injection, intravenous injection, intramuscular injection or intralesional injection; A method for treating or preventing a tumor.

17. The tumor is preferably a tumor expressing CD47, and is preferably a cancer, and the cancer includes solid tumors, blood cancers, lymphomas, blastomas, sarcomas, leukemias, or malignant lymphomas, and more preferably squamous cell carcinomas, myelomas, lung cancers, small cell lung cancers, non-small cell lung cancers, squamous cell carcinomas of the head and neck, gliomas (e.g., gliomas, recurrent gliomas), acute myeloid leukemias, Hodgkin's lymphomas, non-Hodgkin's lymphomas, diffuse large B-cell lymphomas, follicular lymphomas, Acute lymphocytic leukemia, acute promyelocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, primary mediastinal large B-cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, T-cell / histiocyte-rich large B-cell lymphoma, multiple myeloma, myeloid leukemia-1 protein, relapsed or refractory peripheral T-cell lymphoma, myelodysplastic syndrome, anaplastic large cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, myelofibrosis, polycythemia vera, osteomyeloma, bone marrow and and extramedullary proliferation, invasive systemic mastocytosis, eosinophilia, dermatofibrosarcoma protuberans, chronic eosinophilic leukemia, gastrointestinal cancer, gastric cancer or gastroesophageal junction adenocarcinoma, ovarian cancer, liver cancer, lymphocytic leukemia, colorectal cancer, endometrial cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, adenocarcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma, glioblastoma multiforme, bone cancer, Ewing's sarcoma, cervical cancer, nasopharyngeal cancer, brain cancer, bladder cancer, breast cancer, triple-negative breast cancer, intestinal cancer, and rectal cancer. cancer, colorectal cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, clear cell renal cell carcinoma, head and neck cancer, pharyngeal cancer, hepatic and gallbladder cancer, central nervous system cancer, esophageal cancer, esophageal squamous cell carcinoma, malignant pleural mesothelioma, systemic amyloidosis, lymphocytic lymphoma, myeloproliferative neoplasms, neuroendocrine tumors, Merkel cell carcinoma, testicular and skin cancer, peritoneal cancer, fallopian tube cancer, urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer, mesothelioma, A pharmaceutical composition according to any one of claims 1 to 13, a kit according to claim 14 or 15 or a method according to claim 16.

18. A unit dosage form, preferably for use in the treatment of tumors, wherein said unit dosage form contains from 1 mg to 10000 mg (preferably from 10 mg to 1000 mg, more preferably from 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg or 200 mg) of component A and component B as defined in claim 1, When component B is component B1 and / or component B3, the unit dosage form contains 1 mg to 10000 mg (preferably 1 mg to 1000 mg, more preferably 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg, 200 mg or 100 mg) of component B as defined in claim 1, When component B is component B2, the unit dosage form contains 0.1 mg to 100 mg, 0.5 mg to 50 mg, 1 mg to 20 mg, 2 mg to 15 mg, 4 mg to 12 mg or 8 mg to 12 mg of component B; Preferably, the dosage unit further comprises one or more components C as defined in claim 1, wherein the components A, B and C are packaged separately, Unit dosage form.

19. A single pharmaceutical dosage unit, preferably for use in the treatment of tumors, comprising 0.1 mg to 10000 mg (preferably 1 mg to 1000 mg, more preferably 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg, 200 mg or 100 mg) of component A and component B as defined in claim 1, When component B is component B1 and / or component B3, said single pharmaceutical dosage unit contains 0.1 mg to 10000 mg (preferably 1 mg to 1000 mg, more preferably 50 mg to 500 mg, 100 mg to 400 mg, 150 mg to 300 mg, 150 mg to 250 mg, 200 mg or 100 mg) of component B as defined in claim 1, When component B is component B2, the single pharmaceutical dosage unit contains 0.1 mg to 100 mg, 0.5 mg to 50 mg, 1 mg to 20 mg, 2 mg to 15 mg, 4 mg to 12 mg or 8 mg to 12 mg of component B; Single drug dose unit.

Images